[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 194
1. Kim JG, Sung WJ, Kim DH, Kim YH, Sohn SK, Lee KB: Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass. Korean J Intern Med; 2005 Mar;20(1):100-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor in neurofibromatosis type I: unusual presentation of intraabdominal or intrathoracic mass.
  • A malignant peripheral nerve sheath tumor (MPNST) is an extremely rare soft tissue tumor in the general population.
  • On the other hand, there is a higher incidence of MPNST in patients with neurofibromatosis type I (von Recklinghausen's disease).
  • This paper reports two patients, a 31 year-old woman with multiple neurofibromatosis presenting as an intraabdominal malignant peripheral nerve sheath tumor, and a 33 year-old woman with an intrathoracic malignant peripheral nerve sheath tumor.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / complications. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans


2. Matsuda E, Okabe K, Matsuoka T, Hirazawa K, Azuma T, Murakami T, Sugi K: [Lung metastasis of malignant peripheral nerve sheath tumor: report of a case]. Kyobu Geka; 2007 Sep;60(10):950-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung metastasis of malignant peripheral nerve sheath tumor: report of a case].
  • He had underwent extended radical tumorectomy for malignant peripheral nerve sheath tumor (MPNST) in left lower limb 33 months before.
  • Chest X-ray and computed tomography (CT) scan revealed solitary tumor on right S10.
  • Tumor was resected under thoracoscopic surgery.
  • Histological diagnosis was metastasis of MPNST.
  • MPNST with lung metastasis showing very poor prognosis.
  • Careful follow up is important for MPNST.
  • [MeSH-major] Lung Neoplasms / secondary. Nerve Sheath Neoplasms / secondary. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Neurofibromatosis 1 / complications. Prognosis. Survivors. Thoracoscopy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17877020.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Huang W, Zhang X, Li D, Chen J, Meng K, Wang Y, Lu Z, Zhou X: Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts. Virchows Arch; 2006 Feb;448(2):200-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcoma of soft parts.
  • Clear cell sarcoma is a high-grade sarcoma with morphological features resembling those of malignant melanoma.
  • An osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts is very rare.
  • Herein, we report an unusual stomach tumor with microscopic and immunohistochemical characteristics of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • The tumor cells were predominantly oval, admixed with some round and spindle elements arranged in nests and fascicles, and admixed with scattered osteoclast-like multinucleated giant cells.
  • The unusual morphology of the tumor caused significant diagnostic difficulties.
  • The differential diagnosis included gastrointestinal stromal tumor, primary or metastatic melanoma, and epithelioid malignant peripheral nerve sheath tumor.
  • To the best of our knowledge, this is possibly the second description of an osteoclast-rich tumor of the gastrointestinal tract with features resembling those of clear cell sarcomas of soft parts.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Osteoclasts / pathology. Sarcoma, Clear Cell / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Diagnosis, Differential. Giant Cells / chemistry. Giant Cells / pathology. Humans. Immunohistochemistry. Male. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1042-4 [10570398.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):438-40 [10705403.001]
  • [Cites] Adv Anat Pathol. 1999 Jan;6(1):19-40 [10197236.001]
  • [Cites] Arch Pathol Lab Med. 2002 Aug;126(8):972-4 [12171499.001]
  • [Cites] Pathologica. 1998 Aug;90(4):388-90 [9793400.001]
  • [Cites] Int J Surg Pathol. 2003 Apr;11(2):75-81 [12754623.001]
  • [Cites] Ann Thorac Surg. 1985 May;39(5):472-75 [3994450.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4424-7 [9751528.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):969-75 [10491522.001]
  • [Cites] Histopathology. 1993 Mar;22(3):255-9 [7684355.001]
  • [Cites] J Clin Pathol. 2001 Feb;54(2):96-102 [11215292.001]
  • [Cites] Indian J Gastroenterol. 1999 Oct-Nov;18(4):176 [10531723.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):121-4 [9422325.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] Gen Diagn Pathol. 1996 Jun;142(1):63-7 [8793489.001]
  • [Cites] Am Surg. 1992 Jul;58(7):418-22 [1616187.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Gut. 1991 Jul;32(7):828-30 [1855693.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Histopathology. 2002 Dec;41(6):526-30 [12460205.001]
  • [Cites] J Cell Biochem. 1998 Jul 1;70(1):121-9 [9632113.001]
  • (PMID = 16220298.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / S100 Proteins
  •  go-up   go-down


Advertisement
4. Saint-Blancard P, Harket A, Bonnichon A, Jancovici R: [Neurogenic spindle-cell tumors of the mediastinum: two cases]. Presse Med; 2008 Feb;37(2 Pt 1):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurogenic spindle-cell tumors of the mediastinum: two cases].
  • INTRODUCTION: Neurogenic tumors can develop from neural cells in any location.
  • Neurogenic tumors can be benign or malignant.
  • CASES: We report one case of a malignant peripheral nerve sheath tumor in the posterior mediastinum of a 29-year-old man and another of a schwannoma of the anterior mediastinum, in an 82-year-old woman.
  • DISCUSSION: Neurogenic tumors of spindle-shaped cells in the mediastinum are generally benign, but can be malignant.
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988829.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Wimmer K: [Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome]. Wien Med Wochenschr; 2005 Jun;155(11-12):273-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurofibromatosis: the most frequent hereditary tumor predisposition syndrome].
  • [Transliterated title] Neurofibromatose: die häufigste Tumor-disponierende genetische Erkrankung.
  • However, the disorder should not be underestimated as a "mere cosmetic problem", since NF1 patients are at increased risk to also develop malignant tumours, such as malignant peripheral nerve sheath tumours (MPNST), juvenile myelomonocytic leukaemia (JMML), optic glioma and pheochomocytoma.
  • [MeSH-minor] Adolescent. Adult. Child. Chromosome Aberrations. DNA Mutational Analysis. Disease Susceptibility. Genetic Counseling. Genetic Predisposition to Disease / genetics. Genetic Testing. Genotype. Heterozygote Detection. Humans. Neurofibromin 1 / genetics. Neurofibromin 2 / genetics. Phenotype. Risk

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - TUMOR PREDISPOSITION SYNDROME.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035388.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Neurofibromin 2
  •  go-up   go-down


6. Gheisari R, Roozbehi A: Malignant peripheral nerve sheath tumor of the infratemporal fossa. J Craniofac Surg; 2010 Mar;21(2):596-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the infratemporal fossa.
  • Malignant peripheral nerve sheath tumor is a rare pathologic lesion in a patient without neurofibromatosis diseases.
  • Clinical diagnosis of this tumor was made with delay owing to the lack of initial sign and symptoms and its location.
  • [MeSH-major] Facial Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis. Temporal Bone / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Paresthesia / diagnosis. S100 Proteins / analysis. Tomography, X-Ray Computed. Vimentin / analysis

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489461.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


7. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Upadhyaya M: Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol; 2010 Dec;136(12):1869-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
  • OBJECTIVE: Neurofibromatosis type 1 (NF1) patients have a 13% risk of developing a malignant peripheral nerve sheath tumor (MPNST).
  • Many MPNSTs are histopathologically complex, with regions exhibiting features of the original benign plexiform neurofibroma (PNF), of an atypical PNF, or of MPNST showing varying degrees of de-differentiation.
  • This study analyzed the genetic alterations associated with this pathological heterogeneity in order to identify the genetic processes involved in transformation from a benign to an aggressive malignant tumor.
  • METHODS: A histological and molecular analysis of a single MPNST tumor that was subdivided into three histopathologically distinct regions, a benign PNF (region 1), an atypical PNF (region 2), and a high-grade MPNST (region 3), was carried out.
  • Tumor DNA from each region was analyzed in conjunction with the patient's lymphocyte DNA.
  • The NF1-associated LOH analysis found that LOH increased in the three tumor areas, with 9, 42, and 97% LOH evident in regions 1, 2, and 3, respectively.
  • Additional genetic changes, including losses of TP53, RB1, CDKN2A, and of several oncogenes and cell-cycle genes, were found only in the malignant MPNST (region 3).
  • DISCUSSION: This is the first study that correlates the histological and molecular changes associated with MPNST development, confirming the significant cellular and genetic heterogeneity that poses both diagnostic and therapeutic challenges.
  • [MeSH-major] Nerve Sheath Neoplasms / genetics. Neurofibroma / genetics. Neurofibromatosis 1 / genetics. Neurofibromin 1 / genetics
  • [MeSH-minor] Adult. Base Sequence. Comparative Genomic Hybridization. DNA Mutational Analysis. Disease Progression. Germ-Line Mutation. Humans. Loss of Heterozygosity. Male. Molecular Sequence Data


8. Walker JB, Harkey HL, Buciuc R: Percutaneous placement of an external drain of the cisterna magna using interventional magnetic resonance imaging in a patient with a persistent cerebrospinal fluid fistula: technical case report. Neurosurgery; 2008 Aug;63(2):E375; discussion E375
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PRESENTATION: A 28-year-old woman with a previously diagnosed malignant peripheral nerve sheath tumor of the thoracic spine presented with a refractory postoperative cerebrospinal fluid leak complicated by diffuse meningeal carcinomatosis.
  • External lumbar drainage was unsuccessful because of complete tumor obliteration.
  • Ventricular drainage was deferred because of concern for tumor seeding, thus necessitating a more aggressive approach.
  • [MeSH-minor] Adult. Catheterization / instrumentation. Catheterization / methods. Female. Humans. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods. Postoperative Complications / diagnosis. Postoperative Complications / surgery

  • MedlinePlus Health Information. consumer health - Fistulas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797320.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Matono H, Iwamoto Y, Taguchi T, Tsuneyoshi M: Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol; 2010 Jul;23(7):981-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of SMARCB1/INI1 protein in synovial sarcoma.
  • Synovial sarcoma is classified as a tumor of uncertain differentiation, and some synovial sarcomas have rhabdoid cells.
  • In previous studies, all malignant rhabdoid tumors and renal medullary carcinomas, some extraskeletal myxoid chondrosarcomas, almost all epithelioid sarcomas and half of epithelioid malignant peripheral nerve sheath tumors showed a loss of SMARCB1/INI1 protein expression in tumor cells and all of these tumors are also known to have rhabdoid cells.
  • We analyzed the immunohistochemical and mRNA expression of SMARCB1/INI1 in 95 synovial sarcomas (73 monophasic fibrous type, 18 biphasic type and 4 poorly differentiated type) and 30 spindle cell sarcomas (3 adult fibrosarcomas, 7 fibrosarcomas arising in dermatofibrosarcoma protuberans, 10 leiomyosarcomas and 10 malignant peripheral nerve sheath tumors) resembling monophasic fibrous synovial sarcoma.
  • The results have shown that 66 of the 95 synovial sarcoma cases (69%) had reduced SMARCB1/INI1 protein expression, whereas the remaining 29 cases (31%) and all 30 spindle cell sarcomas showed preserved this protein expression.
  • The median values of SMARCB1/INI1 mRNA expression in non-tumor skeletal muscle and synovial sarcoma with reduced protein expression were 12.86 and 134.01, respectively, and a statistically significant difference was detected between these two groups (P=0.0000004).
  • However, there was no statistically significant difference of prognosis between the synovial sarcoma group with reduced and that with preserved SMARCB1/INI1 protein expression (P=0.46).
  • Therefore, it was suggested that there is a post-transcriptional SMARCB1/INI1 regulatory mechanism in the tumor cells of synovial sarcoma.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / biosynthesis. DNA-Binding Proteins / biosynthesis. Sarcoma, Synovial / metabolism. Sarcoma, Synovial / pathology. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Blotting, Western. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305614.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


10. Carlson ML, Babovic-Vuksanovic D, Messiaen L, Scheithauer BW, Neff BA, Link MJ: Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg; 2010 Jan;112(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis Type 2 (NF2) is a rare autosomal dominant disorder characterized by the development of benign tumors of the peripheral nervous system and the CNS, including schwannomas, meningiomas, and ependymomas.
  • The gene responsible for the development of NF2 acts as a tumor suppressor gene.
  • Few reports exist of malignant peripheral nerve sheath tumors, meningiomas, or ependymomas occurring after SRT or stereotactic radiosurgery in patients with NF2.
  • Compared with patients with sporadic tumors, NF2 patients having a germline tumor suppressor gene defect may be more prone to secondary malignancies after treatment involving radiation therapy.
  • [MeSH-minor] Adult. Brain Neoplasms / etiology. Brain Neoplasms / surgery. Brain Stem / pathology. Brain Stem / radiation effects. Brain Stem / surgery. Ear Neoplasms / etiology. Ear Neoplasms / surgery. Fatal Outcome. Female. Humans. Neurilemmoma / etiology. Neurilemmoma / surgery. Vestibular Diseases / etiology. Vestibular Diseases / surgery

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Jan;112(1):209. Scheithauer, Bernd B [corrected to Scheithauer, Bernd W]
  • (PMID = 19575577.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Yang CY, Chou CW, Lin MB, Li CF: Schwannomas of the left adrenal gland and posterior mediastinum. J Chin Med Assoc; 2009 Feb;72(2):83-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannoma is a rare tumor of neural crest cell origin.
  • Pathologic studies showed a picture of benign schwannoma.
  • In conclusion, preoperative differentiation of benign schwannoma from malignant peripheral nerve sheath tumor or other tumors is important for good prognosis.
  • Total excision of benign schwannoma is associated with favourable outcome in patients.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Mediastinal Neoplasms / diagnosis. Neurilemmoma / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251536.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


12. Zhou WX, Zeng X, Liu TH, Wu SF: [Analysis of 13q14 chromosomal instability in soft tissue tumors by fluorescence in-situ hybridization]. Zhonghua Bing Li Xue Za Zhi; 2007 Sep;36(9):582-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-one soft tissue tumors, including 9 benign tumors, 9 tumors of malignant potential and 23 sarcomas, were studied by fluorescence in-situ hybridization (FISH) using dual color probes.
  • One case of malignant peripheral nerve sheath tumor showed amplification at all 3 loci.
  • CONCLUSIONS: A significant percentage of soft tissue tumors exhibited chromosomal instability, reflected by an increase of LOH at tumor-suppressing gene loci.
  • The incidence of 13q abnormality was different in various types of soft tissue tumors, indicating that alterations of Rb, RFP2, KCNRG and KLF5 tumor suppressing genes may play diverse roles in different types of soft tissue tumor.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Gastrointestinal Stromal Tumors / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Young Adult

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070444.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Sengöz A, Taşdemiroğlu E, Togay H: Is clear cell sarcoma a malignant form of psammomatous melanotic schwannoma? Case report. Neurosurg Focus; 2006;21(6):E11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is clear cell sarcoma a malignant form of psammomatous melanotic schwannoma? Case report.
  • The authors present a case of clear cell sarcoma (CCS) in which the tumor originated in the S-1 nerve root and had been previously diagnosed as psammomatous melanotic schwannoma (PMS).
  • This is the third case of a spinal nerve root origin for CCS reported in the English-language literature.
  • The similar histogenesis of CCS and malignant melanoma supports the hypothesis that biological agents or immunotherapy are potentially important areas of investigation.
  • The border of the resection was extended 1 cm distal to the tumor margin.
  • The new histopathological diagnosis was CCS (malignant melanoma of soft tissue).
  • A CCS originating from peripheral nerves is quite rare.
  • [MeSH-major] Neurilemmoma / classification. Peripheral Nervous System Neoplasms / classification. Sarcoma, Clear Cell / classification. Spinal Nerve Roots / pathology
  • [MeSH-minor] Adolescent. Adult. Antigens, Neoplasm. Biomarkers, Tumor / analysis. Breast Neoplasms. Diagnosis, Differential. Diagnostic Errors. Female. Fibroadenoma. Humans. Keratins / analysis. Male. Melanins / analysis. Melanoma-Specific Antigens. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local. Neoplasms, Multiple Primary. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / genetics. Nerve Sheath Neoplasms / pathology. Pigmentation Disorders / diagnosis. Pigmentation Disorders / genetics. Prognosis. S100 Proteins / analysis. Sacrococcygeal Region. Syndrome. Vimentin / analysis

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341045.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Melanins; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / S100 Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 17
  •  go-up   go-down


14. Shimizu K, Okita R, Uchida Y, Hihara J: Long survival after resection for lung metastasis of malignant peripheral nerve sheath tumor in neurofibromatosis 1. Ann Thorac Cardiovasc Surg; 2008 Oct;14(5):322-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long survival after resection for lung metastasis of malignant peripheral nerve sheath tumor in neurofibromatosis 1.
  • A 31-year-old man with neurofibromatosis 1 (NF1) was admitted for the treatment of solitary lung tumor.
  • Nine months earlier he had undergone a large resection for malignant peripheral nerve sheath tumors (MPNSTs) in his back.
  • Surgical resection of the right lower lobe was performed, and the tumor was pathologically diagnosed as a metastasis of MPNST.
  • The survival of patients with pulmonary metastasis of MPNST is extremely poor, especially of those with NF1, but this patient has survived 5 years without recurrence.
  • [MeSH-major] Lung Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Neurofibromatosis 1 / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Humans. Male. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18989250.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Sanchez-Mejia RO, Pham DN, Prados M, Tihan T, Cha S, El-Sayed I, McDermott MW: Management of a sporadic malignant subfrontal peripheral nerve sheath tumor. J Neurooncol; 2006 Jan;76(2):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of a sporadic malignant subfrontal peripheral nerve sheath tumor.
  • Malignant subfrontal (olfactory) peripheral nerve sheath tumors (MPNSTs) are exceedingly rare.
  • In this paper, we describe a patient with a subfrontal MPNST with unusual histological characteristics and present a review of the literature.
  • The patient underwent both a bifrontal transbasal craniotomy and a transnasal approach for an attempt at total resection of both the intradural and extradural components of the MPNST.
  • The specific cell and nerve of origin for these tumors remains unknown.
  • Our case shows that these rare lesions can present as a malignant variant and thus require aggressive surgical and postoperative management to provide long-term tumor control.
  • [MeSH-major] Brain Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Craniotomy. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Olfaction Disorders / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2002 Apr;12(4):742-4 [11960220.001]
  • [Cites] Singapore Med J. 2001 Jun;42(6):275-7 [11547967.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(5):401-5 [8116230.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Jan;124(1):109,111-2 [9440794.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Neurologia. 2000 Nov;15(9):404-5 [11195149.001]
  • [Cites] Clin Neurol Neurosurg. 1999 Mar;101(1):26-8 [10350200.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Apr;44(4):191-4 [15185758.001]
  • [Cites] Zentralbl Neurochir. 1968;29(4):217-22 [5731427.001]
  • [Cites] Neurosurgery. 1997 Jan;40(1):194-7 [8971843.001]
  • [Cites] Neurol India. 2004 Jun;52(2):261-2 [15269489.001]
  • [Cites] Clin Neurol Neurosurg. 1995 May;97(2):187-91 [7656497.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(6):671-2 [10929737.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 16132491.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, Zhang W, McCutcheon IE, Slopis JM, Lazar AJ, Pollock RE, Lev D: Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg; 2009 Jun;249(6):1014-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome.
  • OBJECTIVE: Improved staging systems for malignant peripheral nerve sheath tumor (MPNST) prognostication and management are needed.
  • Consequently, we sought to identify clinical, pathologic, and molecular predictors of outcome in patients with/without neurofibromatosis type 1 (NF-1) associated MPNST.
  • METHODS: MPNST patients treated from 1986 to 2006 (n = 140) were identified; 72 had NF-1 syndrome and 68 did not.
  • Paraffin-embedded neurofibroma or MPNST blocks were assembled in a tissue microarray; marker expression was evaluated immunohistochemically.
  • The 5 years DSS for localized tumor patients was 35% for NF-1 patients and 50% for sporadic patients.
  • MPNST >or=10 cm at diagnosis, partial resection, and metastasis development were significant negative predictors of DSS; completely resected tumors that lacked S-100 immunoreactivity had a nearly 5-fold increased risk of developing distant metastasis.
  • Ki67, vascular endothelial growth factor, p53, and pMEK were over-expressed in MPNST compared with benign neurofibromas.
  • Only tumor size and nuclear p53 expression were found to be independent prognosticators for MPNST DSS in a multivariable analysis.
  • CONCLUSIONS: MPSNT is a markedly metastatic and aggressive poor prognosis tumor.
  • Multiple clinical, pathologic, and molecular markers identified in this study, coupled with findings from previous series, should be considered for an improved MPNST staging system useful for prognostic assessment and management decisions.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Nerve Sheath Neoplasms / metabolism. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Neurofibromatosis 1 / complications. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474676.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


17. Spurlock G, Griffiths S, Uff J, Upadhyaya M: Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam Cancer; 2007;6(4):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types.
  • We have carried out NF1 gene mutation analysis on DNA isolated from 25 tumours (dermal and plexiform neurofibromas, malignant peripheral nerve sheath tumour, MPNST), obtained at post-mortem from an NF1 patient.
  • [MeSH-minor] Adolescent. Adult. Alleles. Base Sequence. Child, Preschool. Chromatography, High Pressure Liquid. Exons / genetics. Gene Deletion. Humans. Microsatellite Instability. Molecular Sequence Data. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1988 Dec;111 ( Pt 6):1355-81 [3145091.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):893-904 [16830335.001]
  • [Cites] Hum Genet. 2003 Feb;112(2):117-23 [12522551.001]
  • [Cites] Hum Mutat. 2003 Dec;22(6):423-7 [14635100.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):393-401 [10677298.001]
  • [Cites] Hum Genet. 2001 May;108(5):416-29 [11409870.001]
  • [Cites] Am J Med Genet. 1997 May 16;70(2):138-43 [9128932.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):111-6 [14722914.001]
  • [Cites] Acta Derm Venereol. 1995 Mar;75(2):136-40 [7604643.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Hum Mutat. 2006 Oct;27(10 ):1030-40 [16941471.001]
  • [Cites] Hum Mutat. 1997;9(5):458-64 [9143927.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12 ):e57 [12060695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):346-50 [9177273.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):290-3 [9927033.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):359-62 [11809679.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):65-9 [10459349.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):44-9 [10633134.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):790-818 [10712197.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Am J Hum Genet. 1994 Mar;54(3):424-36 [8116612.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):110-2 [8782831.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1387-92 [11440991.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • (PMID = 17551851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


18. Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A: Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery; 2009 Oct;65(4 Suppl):A160-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
  • OBJECTIVE: Benign plexiform neurofibromas (PNfib), especially those occurring in patients with neurofibromatosis type 1, are at a significant risk of progressing to a malignant peripheral nerve sheath tumor (MPNST).
  • Early diagnosis, followed by radical surgery and adjuvant radiation to maintain local tumor control, is of critical importance to prevent metastasis and subsequent mortality from MPNSTs.
  • However, early diagnosis is hampered by the sensitivity of current imaging modalities such as computed tomography (CT) or magnetic resonance imaging to reliably detect this malignant transformation, which can occur heterogeneously in a PNfib to a MPNST.
  • METHODS: In this prospective study, 9 neurofibromatosis type 1-associated PNfibs suspected to have undergone transformation to an MPNST were preoperatively evaluated by 18FDG-PET/CT and magnetic resonance imaging.
  • A detailed histological evaluation correlated the average and regional standard uptake value (SUV) from the 18FDG-PET/CT to grade of malignancy of the suspected MPNST.
  • Stratification of the maximal SUV to low (<4.0), intermediate (4.0-7.0), or high (>7.0) correlated to the proliferative index (Ki-67) and grade of MPNST.
  • A maximal SUV of more than 7.0 was closely correlated to a focus of malignant transformation.
  • [MeSH-major] Nerve Sheath Neoplasms / radionuclide imaging. Neurofibroma / radionuclide imaging. Neurofibromatosis 1 / radionuclide imaging. Peripheral Nerves / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Predictive Value of Tests. Prospective Studies. Tomography, X-Ray Computed. Young Adult


19. Widemann BC: Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep; 2009 Jul;11(4):322-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas that rarely occur in the general population but have a lifetime incidence of 8% to 13% in those with neurofibromatosis type 1 (NF1).
  • The response rate of MPNSTs to standard chemotherapeutic agents used to treat pediatric and adult soft tissue sarcomas is unknown and is currently undergoing evaluation in a multi-institutional clinical trial.
  • This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy.
  • [MeSH-major] Nerve Sheath Neoplasms / genetics. Nerve Sheath Neoplasms / therapy. Neurofibromatosis 1 / complications
  • [MeSH-minor] Clinical Trials as Topic. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Genome-Wide Association Study. Nuclear Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Protein p73. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics. Vascular Endothelial Growth Factor A / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 May 15;47(10):2503-9 [6791802.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):23-37 [14984765.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4507-13 [12154062.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1337-45 [14508395.001]
  • [Cites] J Pediatr. 1997 Nov;131(5):678-82 [9403645.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):791-6 [11821462.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1237-45 [18483311.001]
  • [Cites] J Neurosci Res. 2005 Nov 15;82(4):465-71 [16235251.001]
  • [Cites] Nature. 1992 Apr 23;356(6371):713-5 [1570015.001]
  • [Cites] Hum Mutat. 2008 Jan;29(1):74-82 [17960768.001]
  • [Cites] Histopathology. 2001 Aug;39(2):187-97 [11493336.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1015-24 [18281533.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Curr Biol. 2008 Jan 8;18(1):56-62 [18164202.001]
  • [Cites] J Cell Physiol. 1998 Nov;177(2):334-42 [9766530.001]
  • [Cites] Cancer Treat Rep. 1985 May;69(5):499-504 [3924401.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):863-6 [2498525.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1233-41 [10791998.001]
  • [Cites] Radiology. 2009 Mar;250(3):665-73 [19244040.001]
  • [Cites] Am J Med Genet. 1997 Dec 12;73(2):197-204 [9409873.001]
  • [Cites] Cancer. 1973 Aug;32(2):426-39 [4198700.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):205-11 [16043787.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Cancer. 1983 Mar 15;51(6):1028-33 [6821867.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Apr;12(2):355-68 [12916459.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):548-54; discussion 571-2, 646-51 [12403552.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] Arch Surg. 1981 Jun;116(6):765-9 [7235973.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):390-4 [17932395.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):57-61 [11438454.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):593-8 [18559970.001]
  • [Cites] Neurosurg Clin N Am. 2008 Oct;19(4):533-43, v [19010279.001]
  • [Cites] Neuroradiology. 2003 Sep;45(9):618-25 [12898075.001]
  • [Cites] Exp Dermatol. 2003 Aug;12(4):412-7 [12930297.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] J Neurooncol. 2009 Sep;94(3):383-8 [19330289.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2543-9 [3922610.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):65-9 [10459349.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Am J Med Genet A. 2005 Jan 1;132A(1):49-53 [15523617.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1520-8 [18316617.001]
  • [Cites] Ann Surg Oncol. 1995 Nov;2(6):524-9 [8591083.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1885-91 [10595919.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1253-65 [2119249.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):31-7 [10469434.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):351-60 [9788415.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):573-7; discussion 602-4, 646-51 [12403555.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):847-52 [16585951.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):1-5 [3791140.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2755-60 [15805275.001]
  • [Cites] Cancer Chemother Rep. 1970 Feb;54(1):65-8 [5527013.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1537-45 [7602342.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):507-13 [8637706.001]
  • [Cites] Expert Rev Anticancer Ther. 2002 Apr;2(2):201-15 [12113242.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5536-41 [10554031.001]
  • [Cites] Carcinogenesis. 2006 Mar;27(3):664-71 [16357008.001]
  • [Cites] Neurology. 2002 May 28;58(10):1461-70 [12041525.001]
  • [Cites] Acta Neuropathol. 2004 Feb;107(2):159-68 [14673600.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):65-75 [15652750.001]
  • [Cites] Neoplasia. 2007 Aug;9(8):671-7 [17786186.001]
  • (PMID = 19508838.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / TP53 protein, human; 0 / Tumor Protein p73; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 80
  •  go-up   go-down


20. Puhaindran ME, Athanasian EA: Double ray amputation for tumors of the hand. Clin Orthop Relat Res; 2010 Nov;468(11):2976-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Partial hand amputations for malignant tumors allow tumor resection with negative resection margins, which is associated with lower local recurrence rates and improved overall survival while preserving native tissue, which improves functional outcome.
  • All five patients had high-grade soft tissue sarcomas of the hand, two synovial sarcomas, two malignant peripheral nerve sheath tumors, and one undifferentiated sarcoma.
  • No patients developed local tumor recurrence.
  • Functional assessment showed a mean Musculoskeletal Tumor Society score of 24 (range, 19-28) and mean grip strength 24% of the contralateral side (range, 17%-35%).
  • CONCLUSIONS: Although double ray amputation results in worse functional outcome than single ray, good key, tip, and tripod pinch can be preserved when the deep motor branch of the ulnar nerve is preserved, and this hand can still assist in bimanual hand activities.
  • [MeSH-major] Amputation. Hand / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Disease-Free Survival. Hand Strength. Humans. Middle Aged. Neoplasm Recurrence, Local. New York City. Recovery of Function. Retrospective Studies. Time Factors. Treatment Outcome. Ulnar Nerve / physiopathology. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Orthop (Belle Mead NJ). 2000 Mar;29(3):226-8 [10746475.001]
  • [Cites] Orthop Clin North Am. 1981 Oct;12(4):763-803 [7322509.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] J Bone Joint Surg Am. 1995 Apr;77(4):564-71 [7713973.001]
  • [Cites] Clin Orthop Relat Res. 2010 May;468(5):1390-5 [19655212.001]
  • [Cites] J Hand Surg Am. 2006 Mar;31(3):452-5 [16516741.001]
  • [Cites] J Bone Joint Surg Br. 2008 Feb;90(2):209-14 [18256090.001]
  • [Cites] J Hand Surg Eur Vol. 2008 Jun;33(3):358-62 [18450795.001]
  • [Cites] J Hand Surg Am. 1997 May;22(3):495-503 [9195461.001]
  • (PMID = 20490732.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2947675
  •  go-up   go-down


21. Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR: Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol; 2007 Oct;189(4):928-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of our study was to investigate the use of PET in the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1 (NF1).
  • MATERIALS AND METHODS: Forty-five patients with NF1 who underwent whole-body PET for suspected MPNST based on clinical symptoms or radiologic examinations were retrospectively evaluated.
  • PET may improve preoperative tumor staging by detecting metastases or second primary tumors, which often are present in patients with NF1.
  • [MeSH-major] Fluorodeoxyglucose F18. Methionine / deficiency. Neurofibromatosis 1 / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Isotopes. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885067.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AE28F7PNPL / Methionine
  •  go-up   go-down


22. Rodriguez AO, Truskinovsky AM, Kasrazadeh M, Leiserowitz GS: Case report: Malignant peripheral nerve sheath tumor of the uterine cervix treated with radical vaginal trachelectomy. Gynecol Oncol; 2006 Jan;100(1):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Malignant peripheral nerve sheath tumor of the uterine cervix treated with radical vaginal trachelectomy.
  • BACKGROUND: Malignant peripheral nerve sheath tumors (MPNST) are rare tumors which occur primarily in major nerve trunks and most commonly in patients with neurofibromatosis.
  • CASE: We report a 22-year-old woman with MPNST of the uterine cervix which recurred after loop electrocautery excision and had positive margins on cone biopsy.
  • CONCLUSIONS: MPNST of the uterine cervix is a rare, but potentially aggressive neoplasm.
  • This is the first case of such a tumor treated successfully with preservation of the patients fertility.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Nerve Sheath Neoplasms / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Fertility. Gynecologic Surgical Procedures. Humans


23. Chen L, Mao Y, Chen H, Zhou LF: Diagnosis and management of intracranial malignant peripheral nerve sheath tumors. Neurosurgery; 2008 Apr;62(4):825-32; discussion 832
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of intracranial malignant peripheral nerve sheath tumors.
  • OBJECTIVE: Intracranial malignant peripheral nerve sheath tumors (MPNSTs) are rare and generally carry a poor prognosis.
  • The general strategy was to perform complete resection whenever possible and to provide adjuvant radiotherapy for residual tumor.
  • Total tumor resection was achieved in five patients.
  • There was one case of near total (>90%) and two cases of partial (<90%) tumor removal; the postoperative survival rate was 4, 4, and 2 months, respectively.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Cranial Nerve Neoplasms / surgery. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496188.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Rawal A, Yin Q, Roebuck M, Sinopidis C, Kalogrianitis S, Helliwell TR, Frostick S: Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature. Microsurgery; 2006;26(2):80-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical and malignant peripheral nerve-sheath tumors of the brachial plexus: report of three cases and review of the literature.
  • Tumor involvement of the brachial plexus is uncommon.
  • Malignant peripheral nerve-sheath tumors (MPNST) are rare at this site, arising spontaneously or in the context of NF-1.
  • MPNST are intermediate or high-grade sarcomas with a high risk of local and distant spread.
  • Approximately 50% of MPNST arise in patients with NF-1, and therefore these patients should be thoroughly investigated for any new symptoms or masses.
  • MPNST of the brachial plexus should be treated with an adequate wide local excision, with adjuvant high-dose radiotherapy pre- or postoperatively.
  • The role of chemotherapy in the treatment of MPNST is not clearly defined, but it may have some benefit in salvaging treatment failures.
  • [MeSH-major] Brachial Plexus. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Neurofibromatosis 1 / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538633.001).
  • [ISSN] 0738-1085
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


25. Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC: Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res; 2010 Jan 15;16(2):750-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Ixabepilone is a microtubule-stabilizing agent with activity in adult solid tumors and in pediatric tumor xenograft models that are resistant to paclitaxel.
  • This study aimed to determine the response rate to ixabepilone in six solid tumor strata in children and young adults.
  • EXPERIMENTAL DESIGN: We conducted a phase II trial of ixabepilone (8 mg/m(2)/dose for 5 days every 21 days) using a two-stage design in taxane-naïve children and young adults with treatment-refractory, measurable rhabdomyosarcoma, Ewing sarcoma family tumors, osteosarcoma, synovial sarcoma, or malignant peripheral nerve sheath tumor, neuroblastoma, and Wilms tumor.
  • Seven patients received >or=3 cycles, and two had prolonged stable disease (Wilms' tumor, 38 cycles; synovial sarcoma, 8 cycles).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ixabepilone .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8 [16203787.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81 [11464982.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1866-73 [12721265.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):2015-25 [15143095.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2324-9 [7902425.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1538-43 [9193350.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):733-7 [10213206.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2726-34 [15837987.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1821-8 [16532433.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3421-7 [17606971.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3415-20 [17606972.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3399-406 [17606975.001]
  • [Cites] Ann Oncol. 2007 Sep;18(9):1548-53 [17761711.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1207-23 [19088324.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):550-6 [19075272.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]
  • (PMID = 20068084.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA 98543; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Epothilones; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ NIHMS160304; NLM/ PMC3086796
  •  go-up   go-down


26. Yildirim G, Gillenwater AM, Ordonez NG, Garden AS, El-Naggar AK: Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease. Head Neck; 2008 May;30(5):675-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease.
  • A 1.5-cm papillary thyroid carcinoma was identified in thyroidectomy and an initial diagnosis of undifferentiated malignant neoplasm was rendered on the neck mass biopsy.
  • Subsequent surgical excision of the neck mass and immunohistochemical analysis revealed malignant peripheral nerve sheath tumor.
  • Rare malignancies including malignant peripheral nerve sheath tumor may be encountered along with the more common papillary thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / pathology. Neoplasms, Second Primary / pathology. Nerve Sheath Neoplasms / pathology. Peripheral Nervous System Neoplasms / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Epithelioid Cells / pathology. Female. Hodgkin Disease / radiotherapy. Humans. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / surgery. Thyroidectomy

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972308.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Salla JT, Johann AC, Garcia BG, Aguiar MC, Mesquita RA: Retrospective analysis of oral peripheral nerve sheath tumors in Brazilians. Braz Oral Res; 2009 Jan-Mar;23(1):43-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of oral peripheral nerve sheath tumors in Brazilians.
  • Traumatic neuroma, neurofibroma, neurilemmoma, palisaded encapsulated neuroma and malignant peripheral nerve sheath tumor (MPNST) are peripheral nerve sheath tumors and present neural origin.
  • The goal of this study was to describe the epidemiological data of oral peripheral nerve sheath tumors in a sample of the Brazilian population.
  • Lesions diagnosed as peripheral nerve sheath tumors were submitted to morphologic and to immunohistochemical analyses.
  • Thirty-five oral peripheral nerve sheath tumors were found, representing 0.16% of all lesions archived in the Oral Pathology Service.
  • Neurilemmoma (4 cases) was more commonly observed in the buccal mucosa.
  • Malignant peripheral nerve sheath tumors (3 cases) occurred in the mandible, palate, and tongue.
  • The data confirmed that oral peripheral nerve sheath tumors are uncommon in the oral region, with some lesions presenting a predilection for a specific gender or site.
  • This study may be useful in clinical dentistry and oral pathology practice and may be used as baseline data regarding oral peripheral nerve sheath tumors in other populations.
  • [MeSH-major] Mouth Neoplasms / epidemiology. Nerve Sheath Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Brazil / epidemiology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. S100 Proteins / analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19488471.001).
  • [ISSN] 1807-3107
  • [Journal-full-title] Brazilian oral research
  • [ISO-abbreviation] Braz Oral Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


28. Levy AD, Patel N, Dow N, Abbott RM, Miettinen M, Sobin LH: From the archives of the AFIP: abdominal neoplasms in patients with neurofibromatosis type 1: radiologic-pathologic correlation. Radiographics; 2005 Mar-Apr;25(2):455-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations of the NF1 gene lead to abnormal tumor suppression.
  • Consequently, patients with NF1 have an increased prevalence of benign and malignant neoplasms throughout the body.
  • There are five categories of NF1 tumors that occur in the abdomen: neurogenic, neuroendocrine, nonneurogenic gastrointestinal mesenchymal, embryonal, and miscellaneous.
  • Malignant peripheral nerve sheath tumor is an aggressive malignancy that is the most common malignant tumor of the abdomen in patients with NF1.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nerve Sheath Neoplasms / diagnosis. Neuroendocrine Tumors / diagnosis. Neurofibroma / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798063.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 77
  •  go-up   go-down


29. Zhang J, Sun Y, Peng ZL: Malignant peripheral nerve sheath tumor of the vagina. Saudi Med J; 2009 May;30(5):705-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the vagina.
  • Malignant peripheral nerve sheath tumors (MPNSTs) usually develop in major nerve trunks, giving rise to tumors in the proximal portions of the upper and lower extremities and trunk.
  • We describe a case of MPNST of the vagina and discuss its diagnosis and treatment.
  • [MeSH-major] Peripheral Nerves / pathology. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417975.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


30. Steigen SE, Schaeffer DF, West RB, Nielsen TO: Expression of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol; 2009 Jul;22(7):914-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The insulin-like growth factor (IGF) system plays an important role in the growth and development of cells and has been implicated in oncogenesis and tumor progression.
  • Of 20 tumor types represented by more than 10 cases, synovial sarcomas, myxoid liposarcomas, GISTs, malignant peripheral nerve sheath tumors, chondrosarcomas, undifferentiated pleomorphic sarcomas (MFH), Ewing's sarcomas and tenosynovial giant cell tumors showed high levels of expression in more than 20% of cases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Gastrointestinal Stromal Tumors / metabolism. Gastrointestinal Stromal Tumors / mortality. Gastrointestinal Stromal Tumors / pathology. Humans. Immunohistochemistry. Male. Mesenchymoma / metabolism. Mesenchymoma / pathology. Middle Aged. Nerve Sheath Neoplasms / metabolism. Nerve Sheath Neoplasms / pathology. Norway / epidemiology. Sarcoma / metabolism. Sarcoma / pathology. Survival Rate. Tissue Array Analysis. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407853.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 112270
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IGF2 protein, human; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


31. Mott RT, Goodman BK, Burchette JL, Cummings TJ: Loss of chromosome 13 in a case of soft tissue perineurioma. Clin Neuropathol; 2005 Mar-Apr;24(2):69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue perineuriomas are rare mesenchymal tumors that are derived from perineurial cells of the peripheral nerve sheath.
  • Histologically, the tumor was composed of a diffuse to fascicular arrangement of spindle cells with bland, elongated nuclei with long, thin, tapering cytoplasmic processes.
  • Although never described in this group of neoplasms, loss of chromosome 13 has been identified in a large number of other soft tissue tumors, particularly sarcomas and malignant peripheral nerve sheath tumors.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 13 / genetics. Nerve Sheath Neoplasms / genetics. Soft Tissue Neoplasms / genetics. Thigh
  • [MeSH-minor] Adult. Female. Humans

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803806.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 65
  •  go-up   go-down


32. James G, Crocker M, King A, Bodi I, Ibrahim A, Chitnavis BP: Malignant triton tumors of the spine. J Neurosurg Spine; 2008 Jun;8(6):567-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant triton tumors of the spine.
  • Malignant triton tumors (MTTs) are malignant peripheral nerve sheath tumors with rhabdomyosarcomatous differentiation.
  • Malignant triton tumors affecting the spine are rare but present special challenges to the neurosurgeon.
  • Nine patients presented with symptoms related to the spinal cord, cauda equina, or nerve root compression.
  • Seven patients had intradural extension of tumor.
  • Malignant triton tumors are rare but should be included in the differential diagnosis of spinal tumors, particularly in patients who have undergone previous radiotherapy or who have neurofibromatosis.
  • [MeSH-major] Neurilemmoma / diagnosis. Spinal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Desmin / analysis. Diagnosis, Differential. Female. Humans. Ki-67 Antigen / analysis. Lumbar Vertebrae / pathology. Male. Neoplasm Recurrence, Local / diagnosis. S100 Proteins / analysis. Sacrum / pathology. Spinal Canal / pathology. Spinal Cord Compression / diagnosis. Thoracic Vertebrae / pathology. Vimentin / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18518679.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Desmin; 0 / Ki-67 Antigen; 0 / S100 Proteins; 0 / Vimentin
  • [Number-of-references] 13
  •  go-up   go-down


33. Fleshman R, Mayerson J, Wakely PE Jr: Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases. Cancer; 2007 Dec 25;111(6):491-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases.
  • BACKGROUND: To the authors' knowledge, few studies exist demonstrating the reliability of fine-needle aspiration (FNA) biopsy for high-grade sarcoma (HGS).
  • Fifty-four cases were diagnosed as HGS, not otherwise specified, 8 as myxofibrosarcoma, 8 as osteosarcoma, 5 as malignant peripheral nerve sheath tumor, 5 as leiomyosarcoma, 4 as Ewing sarcoma, 4 as liposarcoma, 2 as epithelioid sarcoma, and 1 as angiosarcoma.
  • Approximately 71% of patients presented with a primary tumor, 23% with disease recurrence, and 7% with metastasis.
  • [MeSH-major] Biopsy, Fine-Needle. Cytodiagnosis. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Bone Neoplasms / diagnosis. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941014.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


34. Nakagawa Y, Yoshida A, Numoto K, Kunisada T, Wai D, Ohata N, Takeda K, Kawai A, Ozaki T: Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization. Oncol Rep; 2006 Feb;15(2):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances in malignant peripheral nerve sheath tumor detected by metaphase and microarray comparative genomic hybridization.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are highly malignant tumors affecting adolescents and adults.
  • There have been a few reports on chromosomal aberrations of MPNSTs; however, the tumor-specific alteration remains unknown.
  • [MeSH-major] Chromosome Aberrations. Nerve Sheath Neoplasms / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Child. Female. Gene Dosage. Humans. Male. Metaphase. Middle Aged. Reproducibility of Results


35. Snyder LA, Linder KE, Neel JA: Malignant peripheral nerve sheath tumor in a hamster. J Am Assoc Lab Anim Sci; 2007 Nov;46(6):55-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor in a hamster.
  • An adult female golden hamster (Mesocricetus auratus) developed a firm subcutaneous mass on the lateral distal right forelimb that progressed to diffuse limb enlargement accompanied by extensive cutaneous ulceration and drainage and axillary lymph node metastasis.
  • On histology, the invasive neoplasm merged with a large subcutaneous nerve and was composed of spindle cells with a high mitotic index, and lymph node metastasis was confirmed.
  • Histologic morphology and positive immunohistochemical staining of neoplastic cells for vimentin, S100, and neuron-specific enolase were consistent with a malignant peripheral nerve sheath tumor.
  • Although relatively common in dogs, peripheral nerve sheath tumors had not been reported previously in hamsters.
  • [MeSH-major] Mesocricetus. Nerve Sheath Neoplasms / veterinary. Soft Tissue Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17994674.001).
  • [ISSN] 1559-6109
  • [Journal-full-title] Journal of the American Association for Laboratory Animal Science : JAALAS
  • [ISO-abbreviation] J. Am. Assoc. Lab. Anim. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


36. Hachem RN, Bared A, Zeitouni J, Younis RT: Single-stage total endoscopic resection of a plexiform neurofibroma of the maxillary sinus in a child with type 1 neurofibromatosis. Int J Pediatr Otorhinolaryngol; 2010 Apr;74(4):426-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plexiform neurofibromas are peripheral nerve sheath tumors associated with neurofibromatosis type 1.
  • The maxillary sinus is an extremely rare location of the plexiform neurofibroma and only two adult cases have been previously reported.
  • This unusual location presents a management challenge considering the infiltrative nature and the potential malignant degeneration of this type of tumor.
  • Due to the location of the tumor and the patient's age, conservative surgery is highly recommended.
  • We performed an endoscopic total en-bloc resection of the tumor with no recurrence after nine months of follow-up.


37. Klijanienko J, Caillaud JM, Lagacé R: Cytohistologic correlations in schwannomas (neurilemmomas), including "ancient," cellular, and epithelioid variants. Diagn Cytopathol; 2006 Aug;34(8):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannoma accounts for one of the most common benign mesenchymal neoplasms of soft tissues.
  • No example of melanotic schwannoma was recorded.
  • Original cytologic diagnosis was schwannoma in 13 (38.2%) cases, benign soft tissue tumor in 11 (32.4%), pleomorphic adenoma in 2 (6%) cases, angioma in 1 (2.9%) case, nodular fasciitis in 1 (2.9%) case, suspicious in 3 (8.8%) cases, and not satisfactory in 3 (8.8%) cases.
  • Schwannoma should be differentiated from well-differentiated malignant peripheral nerve sheath tumor, neurofibroma, and pleomorphic adenoma, in the last instance particularly for head and neck lesions.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16850489.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Zheng L, Zhang JG, Yu GY, Gao Y: [Malignant peripheral nerve sheath tumors in oral maxillofacial region: clinical analysis of 11 cases]. Beijing Da Xue Xue Bao; 2010 Apr 18;42(2):216-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peripheral nerve sheath tumors in oral maxillofacial region: clinical analysis of 11 cases].
  • OBJECTIVE: To investigate the clinicopathologic features, treatment and prognosis of the malignant peripheral nerve sheath tumors (MPNST) in oral and maxillofacial region.
  • CONCLUSION: MPNST is one of the most aggressive tumors with high risk of local recurrence and distant metastasis.
  • Complete removal of the tumor is the main modality of treatment and a most important prognostic factor of MPNST.
  • [MeSH-major] Mandibular Neoplasms / diagnosis. Maxillary Neoplasms / diagnosis. Mouth Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396368.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


39. Puhaindran ME, Steensma MR, Athanasian EA: Partial hand preservation for large soft tissue sarcomas of the hand. J Hand Surg Am; 2010 Feb;35(2):291-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with large soft tissue sarcomas of the hand, partial hand preservation is extremely challenging for surgeons attempting a complete resection of the tumor with negative resection margins.
  • We identified 8 patients who had tumors at least 5 cm in maximum dimension and had tumor resection with partial hand preservation.
  • Two patients had myxofibrosarcoma, 2 patients had synovial sarcoma, 2 patients had malignant fibrous histiocytoma, 1 patient had a malignant peripheral nerve sheath tumor, and 1 patient had a liposarcoma.
  • Hand function was evaluated using Musculoskeletal Tumor Society criteria.
  • RESULTS: Of the 8 patients, 1 died of distant metastatic disease, 1 developed local tumor recurrence and is alive with locally recurrent disease, and the other 6 patients are completely disease-free.
  • The mean Musculoskeletal Tumor Society score was 26 (range, 19-29), with the 2 patients who had received double-ray amputations having the lower scores (19 and 24).
  • [MeSH-major] Hand / surgery. Limb Salvage / methods. Neoplasm Recurrence, Local / pathology. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / methods. Arm. Artificial Limbs. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prosthesis Fitting. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20141899.001).
  • [ISSN] 1531-6564
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Park SK, Yi HJ, Paik SS, Kim YJ, Ko Y, Oh SJ: Metastasizing malignant peripheral nerve sheath tumor initially presenting as intracerebral hemorrhage. Case report and review of the literature. Surg Neurol; 2007 Jul;68(1):79-84; discussion 84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing malignant peripheral nerve sheath tumor initially presenting as intracerebral hemorrhage. Case report and review of the literature.
  • BACKGROUND: Malignant peripheral nerve sheath tumors, infrequent sarcomas arising within a peripheral nerve, mostly metastasize to the lung at terminal stage of disease.
  • Surgical removal and adjuvant therapy was performed for pathologically proven MPNST.
  • Concurrent painful chest masses were also confirmed as MPNST through surgical resection.
  • The MPNST actually can exhibit an apoplectic manifestation even without pulmonary involvement in a young adult, albeit this is quite rare.
  • Thus, high index of suspicion should be paid to minute complaints regarding MPNST in peripheral locations so as not to overlook an advanced or metastasized disease.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Cerebral Hemorrhage / etiology. Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / secondary. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Craniotomy. Fatal Outcome. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586234.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


41. Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol; 2009 Jul 1;27(19):3148-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
  • PURPOSE The purpose of this trial was to assess the efficacy of imatinib in patients with one of 10 different subtypes of advanced sarcoma.
  • Results One hundred eighty-five assessable patients with one of 10 subtypes of sarcoma were treated.
  • A CBR was achieved in 28 patients treated overall and by subtype: two angiosarcomas (n = 16), 0 Ewing (n = 13), one fibrosarcoma (n = 12), six leiomyosarcomas (n = 29), seven liposarcomas (n = 31), three malignant fibrous histiocytomas (n = 30), five osteosarcomas (n = 27), one malignant peripheral-nerve sheath tumor (n = 7), 0 rhabdomyosarcoma (n = 2), and three synovial sarcomas (n = 22).
  • CONCLUSION This is the first phase II study of a new agent in sarcoma to include sufficient patients with each of the common histologic subtypes to permit generalizable conclusions.
  • Although rare dramatic responses were seen, imatinib is not an active agent in advanced sarcoma in these subtypes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bayes Theorem. Benzamides. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 Sep 20;27(27):4630. Myers, Paul A [corrected to Meyers, Paul A]
  • (PMID = 19451433.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


42. Houreih MA, Eyden B, Deolekar M, Banerjee S: A case of fibroblastic low-grade malignant peripheral nerve sheath tumor--a true neurofibrosarcoma. Ultrastruct Pathol; 2007 Sep-Oct;31(5):347-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of fibroblastic low-grade malignant peripheral nerve sheath tumor--a true neurofibrosarcoma.
  • The authors report a case of low-grade retroperitoneal malignant peripheral nerve sheath tumor (MPNST) showing Schwannian and fibroblastic differentiation in individual tumor cells.
  • The tumor was detected in a 29-year-old male and posed diagnostic difficulty because of the unusual morphologic and immunophenotypic features.
  • Morphologic examination of the H&E sections revealed a rather circumscribed, highly vascular, moderately cellular spindle cell tumor.
  • There were satellite nodules outside the main tumor mass and low mitotic activity but no necrosis.
  • The tumor cells stained strongly and diffusely for both S-100 protein and CD34.
  • Although the capacity of MPNST to exhibit divergent differentiation is well known, fibroblastic differentiation is generally poorly and inconsistently documented.
  • The present case represents an unambiguous demonstration of the co-expression within individual tumor cells of Schwannian and fibroblastic differentiation in a low-grade MPNST.
  • [MeSH-major] Fibroblasts / pathology. Nerve Sheath Neoplasms / pathology. Neurofibrosarcoma / pathology
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Humans. Male. Microscopy, Electron, Transmission. S100 Proteins / analysis. Schwann Cells / ultrastructure

  • Genetic Alliance. consumer health - Neurofibrosarcoma.
  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963184.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


43. Furniss D, Swan MC, Morritt DG, Lim J, Khanna T, Way BL, Athanasou NA, Giele H, Critchley P: A 10-year review of benign and malignant peripheral nerve sheath tumors in a single center: clinical and radiographic features can help to differentiate benign from malignant lesions. Plast Reconstr Surg; 2008 Feb;121(2):529-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 10-year review of benign and malignant peripheral nerve sheath tumors in a single center: clinical and radiographic features can help to differentiate benign from malignant lesions.
  • BACKGROUND: Malignant peripheral nerve sheath tumors are rare, and their aggressive nature mandates treatment in specialist centers.
  • In contrast, benign peripheral nerve sheath tumors are common and are treated by a variety of specialist surgeons, including plastic surgeons.
  • The authors aimed to detect features in the clinical presentation of peripheral nerve sheath tumors that point toward a diagnosis of malignant peripheral nerve sheath tumor and therefore prompt referral to a specialist center.
  • METHODS: All histologically diagnosed primary peripheral nerve sheath tumors from January of 1995 to December of 2004 were identified from histopathology records.
  • RESULTS: During the study period, 32 cases of malignant peripheral nerve sheath tumor in 30 patients were treated.
  • Factors in the clinical evaluation that significantly predicted the presence of malignant peripheral nerve sheath tumor included site, large size, depth in relation to the deep fascia, short duration of symptoms, and pain.
  • Interestingly, schwannomata were harder to distinguish from malignant peripheral nerve sheath tumors both clinically and radiologically.
  • CONCLUSIONS: The authors have reviewed their institutional experience of peripheral nerve sheath tumors over a 10-year period.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neurilemmoma / diagnosis. Neurofibroma / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300972.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


44. Kumar P, Jaiswal S, Agrawal T, Verma A, Datta NR: Malignant peripheral nerve sheath tumor of the occipital region: case report. Neurosurgery; 2007 Dec;61(6):E1334-5; discussion E1335
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of the occipital region: case report.
  • OBJECTIVE: A rare case of a malignant peripheral nerve sheath tumor of the occipital region is presented.
  • INTERVENTION: A small occipital craniectomy for total excision of the tumor was attempted.
  • However, as a result of intracranial extension to the transverse sinus, the tumor could not be completely excised.
  • CONCLUSION: An aggressive malignant peripheral nerve sheath tumor of an atypical site such as the scalp, in which complete surgery may not always be possible, could benefit from postoperative radiotherapy.
  • [MeSH-major] Brain Neoplasms. Nerve Sheath Neoplasms. Occipital Lobe / pathology
  • [MeSH-minor] Adult. Craniotomy / methods. Humans. Male. Tomography, X-Ray Computed / methods


45. Gong YL, Li T, Guo H, Sun Y, Chi YK, Ling Y, Shen Q, Liu HJ, Hou L, Zhang B: [Expression of TEIF protein in soft tissue tumors and its significance]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):651-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of TEIF in 166 cases of sarcomas and 28 case benign tumors or tumor-like lesions of soft tissue arranged in tissue chip was analyzed by immunohistochemistry.
  • The immunohistochemical staining of TEIF showed that about 58% (97/166) of sarcomas were positive and significantly different from that of benign tumors or tumor-like lesions (11%, 3/28).
  • The positive staining was predominantly in synovial sarcoma 94% (16/17), primitive neuroectodermal tumor (PNET) 91% (21/23), both of which were significantly higher than 43% (6/14) of dermatofibrosarcoma protuberans, 38% (6/16) of myxofibrosarcoma, 36% (8/22) of malignant peripheral nerve sheath tumor, 32% (6/19) of liposarcoma, (P < 0.05, respectively), but not higher than 75% (15/20) of malignant fibrous histiocytoma, 70% (7/10) of rhabdomyosarcoma or 64% (9/14) of leiomyosarcoma.
  • Meanwhile, strong positive staining of TEIF (>or= 2+) was frequently observed in PNET (83%, 19/23) and synovial sarcoma (76%, 13/17).
  • With respect to FNCLCC grading, 19 cases of grade I sarcoma TEIF was 32% (6/19) and strong positive was 11% (2/19), 44 cases of grade II sarcoma was 48% (21/44) and 32% (14/44), and 70 of grade III was 84% (59/70) and 70% (49/70).
  • The rate of either positive or strong positive in grade III sarcoma was significantly different from that of either grade I or II (P < 0.05), but no difference between the latter two groups (P > 0.05).
  • [MeSH-major] Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Child. Child, Preschool. Female. HeLa Cells. Histiocytoma, Malignant Fibrous / metabolism. Histiocytoma, Malignant Fibrous / pathology. Humans. Immunohistochemistry. Infant. Leiomyoma / metabolism. Leiomyoma / pathology. Male. Middle Aged. Neuroectodermal Tumors, Primitive / metabolism. Neuroectodermal Tumors, Primitive / pathology. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / pathology. Sarcoma, Synovial / metabolism. Sarcoma, Synovial / pathology. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374207.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Transcription Factors; EC 2.7.1.- / SCYL1 protein, human
  •  go-up   go-down


46. Matsumine A, Shintani K, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Iino T, Uchida A: Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol; 2007 Oct 1;96(5):411-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lower levels of decorin were expressed in liposarcoma and malignant peripheral nerve sheath tumor than in lipoma (<0.01) and neurofibroma (P < 0.05), respectively.
  • An immunohistochemical analysis for spindle-cell sarcomas demonstrated decorin protein to be produced by myofibroblastic cells in the peripheral stromal extracellular spaces.
  • CONCLUSIONS: A reduced decorin expression was found to be a useful biomarker of aggressiveness in soft tissue tumor.
  • [MeSH-major] Extracellular Matrix Proteins / metabolism. Neoplasms, Connective and Soft Tissue / metabolism. Nerve Sheath Neoplasms / metabolism. Proteoglycans / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Child. Child, Preschool. DNA, Neoplasm / metabolism. Decorin. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Proportional Hazards Models. RNA, Neoplasm / metabolism. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579351.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DCN protein, human; 0 / DNA, Neoplasm; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans; 0 / RNA, Neoplasm
  •  go-up   go-down


47. Pasmant E, Ortonne N, Rittié L, Laurendeau I, Lévy P, Lazar V, Parfait B, Leroy K, Dessen P, Valeyrie-Allanore L, Perbal B, Wolkenstein P, Vidaud M, Vidaud D, Bièche I: Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis. J Neuropathol Exp Neurol; 2010 Jan;69(1):60-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 1 patients with plexiform neurofibromas are at risk of developing malignant peripheral nerve sheath tumors.
  • Several CCN gene family members were dysregulated in neurofibromatosis type 1 tumorigenesis; the angiogenic gene CCN1/CYR61 was specifically upregulated in the plexiform neurofibromas; CCN4/WISP1 was upregulated, and CCN3/NOV and CCN5/WISP2 were downregulated in paired comparisons of plexiform neurofibroma and malignant peripheral nerve sheath tumor from the same patients.
  • [MeSH-minor] Adolescent. Adult. CCN Intercellular Signaling Proteins. Carcinogenicity Tests / methods. Cell Differentiation / genetics. Cells, Cultured. Cysteine-Rich Protein 61 / genetics. Cysteine-Rich Protein 61 / metabolism. Female. Gene Expression Profiling / methods. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Male. Middle Aged. Nephroblastoma Overexpressed Protein / genetics. Nephroblastoma Overexpressed Protein / metabolism. Oligonucleotide Array Sequence Analysis / methods. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. RNA, Messenger / metabolism. Repressor Proteins. Schwann Cells / physiology. Statistics, Nonparametric. Transcription Factors / genetics. Transcription Factors / metabolism. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010302.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCN Intercellular Signaling Proteins; 0 / CYR61 protein, human; 0 / Cysteine-Rich Protein 61; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / NOV protein, human; 0 / Nephroblastoma Overexpressed Protein; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / WISP1 protein, human; 0 / WISP2 protein, human
  •  go-up   go-down


48. Aoki M, Nabeshima K, Nishio J, Ishiguro M, Fujita C, Koga K, Hamasaki M, Kaneko Y, Iwasaki H: Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization. Int J Oncol; 2006 Dec;29(6):1421-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization.
  • Malignant peripheral nerve sheath tumor (MPNST) is a rare malignant tumor, for which only a few cultured cell lines are available to date.
  • In the present study, we established three new MPNST cell lines, FU-SFT8611, FU-SFT8710 and FU-SFT9817, from a 40-year-old Japanese man without neurofibromatosis 1 (NF1), a 43-year-old Japanese woman with NF1, and a 61-year-old Japanese woman without NF1, respectively.
  • These newly established cell lines provide a valuable resource for biological and pathological investigations into new treatment regimes for MPNST.
  • [MeSH-major] Cell Line, Tumor. Nerve Sheath Neoplasms / genetics
  • [MeSH-minor] Adult. Animals. Cell Growth Processes / physiology. Cytogenetic Analysis / methods. Female. Humans. Immunohistochemistry. Karyotyping. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, SCID. Middle Aged. Neoplasm Transplantation. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / pathology. Nucleic Acid Hybridization. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088980.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


49. Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA: DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol Cancer; 2008;7:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
  • BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are rare and highly aggressive soft tissue tumors showing complex chromosomal aberrations.
  • In order to identify recurrent chromosomal regions of gain and loss, and thereby novel gene targets of potential importance for MPNST development and/or progression, we have analyzed DNA copy number changes in seven high-grade MPNSTs using microarray-based comparative genomic hybridization (array CGH).
  • CONCLUSION: Our study shows the potential of using DNA copy number changes obtained by array CGH to predict the prognosis of MPNST patients.
  • [MeSH-major] DNA, Neoplasm / analysis. Gene Dosage. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Nerve Sheath Neoplasms / genetics. Oligonucleotide Array Sequence Analysis. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adenovirus E1A Proteins / genetics. Adult. Aged. Amino Acid Oxidoreductases / genetics. Antigens, Neoplasm / genetics. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 8. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Female. Gene Expression Regulation, Enzymologic. Humans. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / genetics. Middle Aged. Neoplasm Proteins / genetics. Prognosis. Proto-Oncogene Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] BMC Bioinformatics. 2004 Jun 9;5:74 [15189572.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1172-8 [15509679.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Int J Cancer. 1995 Jun 9;61(6):793-8 [7790113.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Sep;14(1):8-14 [8527390.001]
  • [Cites] Monogr Pathol. 1996;38:129-61 [8744276.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4778-81 [8840998.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jul;25(3):205-11 [10379866.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):323-31 [10398425.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):362-9 [10398430.001]
  • [Cites] Am J Med Genet. 1999 Mar 26;89(1):1-6 [10469430.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Oct;26(2):151-60 [10469453.001]
  • [Cites] Bioinformatics. 2005 Mar15;21(6):821-2 [15531610.001]
  • [Cites] Mutat Res. 2005 Aug 25;576(1-2):22-38 [15878778.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):297-303 [16391845.001]
  • [Cites] J Clin Pathol. 2006 Feb;59(2):160-5 [16443732.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8984-93 [16982739.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Trends Mol Med. 2006 Dec;12(12):580-7 [17071139.001]
  • [Cites] J Orthop Res. 2007 Jan;25(1):116-21 [17034065.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):187-92 [17111191.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):644-55 [17394133.001]
  • [Cites] J Pathol. 2000 Jan;190(1):31-8 [10640989.001]
  • [Cites] Cancer Lett. 2000 Jul 31;155(2):181-90 [10822134.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Pathol. 2002 May;197(1):98-107 [12081210.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1657-66 [12670920.001]
  • [Cites] J Pathol. 2003 Aug;200(5):568-76 [12898592.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4586-91 [14673046.001]
  • [Cites] Carcinogenesis. 2004 Mar;25(3):325-32 [14604892.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):69-73 [15346054.001]
  • (PMID = 18522746.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / ETV4 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / LOXL2 protein, human; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2442610
  •  go-up   go-down


50. Shimada S, Tsuzuki T, Kuroda M, Nagasaka T, Hara K, Takahashi E, Hayakawa S, Ono K, Maeda N, Mori N, Illei PB: Nestin expression as a new marker in malignant peripheral nerve sheath tumors. Pathol Int; 2007 Feb;57(2):60-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression as a new marker in malignant peripheral nerve sheath tumors.
  • Malignant peripheral nerve sheath tumor (MPNST) can be difficult to diagnose because it lacks specific immunohistochemical markers.
  • S-100, which is a useful marker of MPNST, has limited diagnostic utility.
  • The diagnostic utility of immunostains for nestin and three other neural markers (S-100, CD56 and protein gene product 9.5 (PGP 9.5)) were evaluated in 35 cases of MPNST and in other spindle cell tumors.
  • All MPNST cases were strongly positive for nestin and had cytoplasmic staining.
  • Nestin was negative in 10/10 leiomyomas, and weak nestin expression was seen in 10/10 schwannomas, 3/10 neurofibromas, 2/8 synovial sarcomas, 2/10 liposarcomas, 4/7 carcinosarcomas and 3/7 malignant fibrous histiocytomas.
  • Nestin is more sensitive for MPNST than other neural markers and immunostains for nestin in combination with other markers could be useful in the diagnosis of MPNST.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Intermediate Filament Proteins / metabolism. Nerve Sheath Neoplasms / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cauda Equina / metabolism. Cauda Equina / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Child. Female. Gene Expression Regulation, Neoplastic. Humans. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Male. Melanoma / metabolism. Melanoma / pathology. Middle Aged. Nestin. Neurilemmoma / metabolism. Neurilemmoma / pathology. Rhabdomyosarcoma / metabolism. Rhabdomyosarcoma / pathology. Sarcoma / metabolism. Sarcoma / pathology. Schwann Cells / metabolism. Schwann Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17300669.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


51. Nepka C, Karadana M, Karasavvidou F, Barbanis S, Kalodimos G, Koukoulis G: Fine needle aspiration cytology of a primary malignant peripheral nerve sheath tumor arising in the parotid gland: a case report. Acta Cytol; 2009 Jul-Aug;53(4):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a primary malignant peripheral nerve sheath tumor arising in the parotid gland: a case report.
  • BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) is an uncommon mesenchymal neoplasm showing nerve sheath differentiation, usually arising in large nerves of the trunk and extremities.
  • We describe fine needle aspiration (FNA) findings in a case of MPNST in the parotid gland.
  • Smears were cellular, with clusters of tightly packed spindle or oval cells arranged in a storiform or whorled pattern, showing clearly malignant features.
  • The background contained abundant necrotic material with dispersed malignant nuclei.
  • Cytologic diagnosis was positive for malignant cells consistent with a spindle cell sarcoma, with morphologic features compatible to neural differentiation, confirmed by histologic examination.
  • CONCLUSION: This case illustrates that attention to moiphologic criteria suggestive of nerve sheath phenotype supported by immunocytochemical data is extremely helpful and reliable in the diagnostic approach to MPNSTs, even in rare locations.
  • [MeSH-major] Biopsy, Fine-Needle. Nerve Sheath Neoplasms / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2010 Sep-Oct;54(5 Suppl):1073-4 [21053609.001]
  • (PMID = 19697728.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O: Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol; 2009 Sep;94(3):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and significance of EGFR in malignant peripheral nerve sheath tumor.
  • Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma.
  • The study was aimed at investigating the expression and prognostic influence of EGFR in MPNST.
  • Forty-three percentage of 46 patients with MPNST overexpressed EGFR in the primary tumor, and had a higher prevalence of advanced-stage tumors (>or=IIc, 46% vs. 80%, P = 0.011).
  • EGFR appeared to play a role in MPNST progression.
  • Clinical trials of targeting EGFR in MPNST are warranted.
  • [MeSH-major] Nerve Sheath Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2009 Sep;94(3):389. Meimon, Natalie [corrected to Maimon, Natalie]
  • [Cites] Oncologist. 2008 Apr;13(4):459-66 [18448562.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4507-13 [12154062.001]
  • [Cites] Cancer. 2005 May 1;103(9):1881-90 [15772959.001]
  • [Cites] Cell Signal. 2007 Oct;19(10):2013-23 [17681753.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):585-90 [16461571.001]
  • [Cites] Sarcoma. 2008;2008:849156 [18769552.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):229-33 [16393679.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] Neurosurg Focus. 2007 Jun 15;22(6):E12 [17613203.001]
  • [Cites] J Surg Oncol. 2007 Mar 1;95(3):183-4 [17323329.001]
  • [Cites] Eur J Surg Oncol. 2006 May;32(4):466-8 [16524687.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Neuro Oncol. 2008 Dec;10 (6):946-57 [18650488.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1792-8 [9667648.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Surg Orthop Adv. 2005 Winter;14(4):168-74 [16442014.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] World J Surg Oncol. 2006 Aug 22;4:55 [16923196.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4057-65 [17827454.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1331-46 [11571750.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Breast Cancer. 2002;9(2):111-7 [12016390.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):65-75 [15652750.001]
  • (PMID = 19330289.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


53. Subhashraj K, Balanand S, Pajaniammalle S: Ancient schwannoma arising from mental nerve. A case report and review. Med Oral Patol Oral Cir Bucal; 2009 Jan;14(1):E12-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ancient schwannoma arising from mental nerve. A case report and review.
  • Schwannoma is an intraoral rare, benign neoplasm derived from the nerve sheath of peripheral nerves.
  • "Ancient schwannoma" shows histopathological features, such as degenerative changes and atypical nuclei, and may easily be confused with malignant neoplasms.
  • Ancient schwannoma of the head and neck region is relatively uncommon and very few cases had been reported in the oral cavity.
  • We present a case of ancient schwannoma arising from the mental nerve in a 19 year old male which was of eight months duration.
  • Ultrasonography showed that the tumor was closely associated with the mental nerve on the left side, suggestive of a peripheral neural sheath tumor.
  • Complete excision of the lesion was done under local anesthesia, preserving the mental nerve.
  • The histological picture was strongly suggestive of ancient schwannoma (Antoni A type).
  • [MeSH-major] Chin / innervation. Neurilemmoma / pathology. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Young Adult

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19114949.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 11
  •  go-up   go-down


54. Upadhyaya M, Kluwe L, Spurlock G, Monem B, Majounie E, Mantripragada K, Ruggieri M, Chuzhanova N, Evans DG, Ferner R, Thomas N, Guha A, Mautner V: Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat; 2008 Jan;29(1):74-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).
  • About 10% of neurofibromatosis type 1 (NF1) patients develop malignant peripheral nerve sheath tumors (MPNSTs) and represent considerable patient morbidity and mortality.
  • Elucidation of the genetic mechanisms by which inherited and acquired NF1 disease gene variants lead to MPNST development is important.
  • The NF1 germline mutation spectrum was similar to that previously identified in adult NF1 patients without MPNST.
  • Somatic NF1 mutations were identified in tumor DNA from 31 out of 34 MPNSTs, of which 28 were large genomic deletions.
  • The high prevalence (>90%) of such deletions in MPNST contrast with the =or<20% found in benign neurofibromas and is indicative of the involvement of different mutational mechanisms in these tumors.
  • [MeSH-major] Germ-Line Mutation. Mutation. Nerve Sheath Neoplasms / genetics. Neurofibromin 1 / genetics. Peripheral Nervous System Neoplasms / genetics
  • [MeSH-minor] Adult. DNA Mutational Analysis. DNA, Neoplasm / metabolism. Humans. Loss of Heterozygosity. Lymphocytes / metabolism. Sequence Deletion. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17960768.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


55. Thomas C, Somani N, Owen LG, Malone JC, Billings SD: Cutaneous malignant peripheral nerve sheath tumors. J Cutan Pathol; 2009 Aug;36(8):896-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignant peripheral nerve sheath tumors.
  • Cutaneous malignant peripheral nerve sheath tumors (MPNSTs) are rare entities compared with their deep soft tissue counterparts.
  • The second case presented in an 88-year-old man with no stigmata of neurofibromatosis as a rapidly growing subcutaneous tumor of the right calf.
  • The diagnosis of MPNST was rendered in both cases.
  • [MeSH-minor] Adult. Aged, 80 and over. Female. Humans. Male. Mitosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586501.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


56. Landy H, Feun L, Markoe A, Patchen S, Bruce J, Marcus J, Levi A: Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report. J Neurosurg; 2005 Oct;103(4):760-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report.
  • Malignant peripheral nerve sheath tumors (MPNSTs) are difficult to control despite aggressive treatment.
  • In this report the authors describe the treatment and follow-up review of a patient with neurofibromatosis Type I who harbored a recurrent median nerve MPNST.
  • Two courses of preoperative intraarterial cisplatin and intravenous Adriamycin produced significant tumor shrinkage.
  • Gross-total removal of the remaining tumor without amputation of the arm was followed by fractionated radiotherapy (total minimum tumor dose 6485 cGy, maximal dose 6575 cGy).
  • The patient is alive 9.5 years after treatment without evidence of tumor recurrence and with only focal median nerve functional deficits.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Nerve Sheath Neoplasms / surgery. Neurofibromatosis 1 / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Male. Treatment Outcome


57. Schittenhelm J, Thiericke J, Nagel C, Meyermann R, Beschorner R: WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy. Cancer Biomark; 2010;7(2):73-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy.
  • OBJECTIVE: Wilms' tumor protein (WT1) expression is usually absent in normal glial cells of the CNS but is highly upregulated in brain tumor cells and its expression correlates with tumor grade.
  • However, knowledge on WT1 expression in tumors of the peripheral nerve system (PNS) is limited.
  • As WT1 antibodies not only serve as biomarker for cancerous tissue but also are considered for cancer immunotherapy, knowledge of WT1 expression in tumorous and normal peripheral nerve tissue is important for therapeutical purposes.
  • METHODS: We analyze the immunohistochemical expression of WT1 in 101 samples consisting of 13 normal nerves, 10 neurofibromas, 69 schwannomas and 9 malignant peripheral nerve sheath tumors (MPNST).
  • Tumor samples included 14 specimen from patients with a proven neurocutaneous disorder (neurofibromatosis type 1 and 2) and 3 cases of schwannomatosis.
  • In 50 vestibular schwannomas tumor growth extension was correlated to WT1 expression.
  • In peripheral nerve sheath tumors, cytoplasmic WT1 protein is expressed in the cytoplasm of the neoplastic cells in all tumors, including MPNST, neurofibromas and schwannomas.
  • The WT1 expression is independent of tumor malignancy or tumor growth extension and is not associated with a neurocutaneous disorder.
  • CONCLUSION: WT1 expression in normal and neoplastic tissue differs in the peripheral and the central nervous system.
  • [MeSH-major] Cranial Nerve Neoplasms / metabolism. Cranial Nerves / metabolism. Nerve Sheath Neoplasms / metabolism. Peripheral Nerves / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Child. Female. Humans. Male. Middle Aged. Neurilemmoma / metabolism. Neurofibroma / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21178265.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


58. Murovic JA, Gibbs IC, Chang SD, Mobley BC, Park J, Adler JR Jr: Foraminal nerve sheath tumors: intermediate follow-up after cyberknife radiosurgery. Neurosurgery; 2009 Feb;64(2 Suppl):A33-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Foraminal nerve sheath tumors: intermediate follow-up after cyberknife radiosurgery.
  • OBJECTIVE: To conduct a retrospective review of outcomes in 15 patients with 18 foraminal tumors, including 17 benign peripheral nerve sheath tumors and 1 malignant peripheral nerve sheath tumor, who underwent CyberKnife (Accuray, Inc., Sunnyvale, CA) radiosurgery at Stanford University Medical Center from 1999 to 2006.
  • METHODS: Symptoms and findings, neurofibromatosis (NF) association, previous radiation, imaging, dosimetry, tumor volume, central necrosis, and the relation of these factors to outcomes were evaluated.
  • Three patients had NF1-associated neurofibromas, 1 patient with NF2 had a schwannoma, and 1 patient had a schwannomatosis-related lesion.
  • Two likely radiation-induced lesions, a neurofibroma and a malignant peripheral nerve sheath tumor, were observed.
  • Prescribed doses ranging from 16 to 24 Gy, delivered in 1 to 3 fractions of 6 to 20 Gy, resulted in maximum tumor doses ranging from 20.9 to 30 Gy.
  • Tumor volumes decreased in 12 (67%) of 18 tumors and increased in 3 tumors.
  • Tumor volumes decreased in 8 of 10 schwannomas and 3 of 7 neurofibromas.
  • CONCLUSION: CyberKnife radiosurgery resulted in pain relief and functional preservation in selected foraminal peripheral nerve sheath tumors and a malignant peripheral nerve sheath tumor.
  • [MeSH-major] Nerve Sheath Neoplasms / surgery. Radiosurgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurofibromatoses / complications. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165072.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, Lim M, Conway SJ, Parada LF, Zhu Y, Morrison SJ: The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell; 2008 Feb;13(2):129-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis is caused by the loss of neurofibromin (Nf1), leading to peripheral nervous system (PNS) tumors, including neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs).
  • However, Nf1-deficient NCSCs did not persist postnatally in regions of the PNS that developed tumors and could not form tumors upon transplantation into adult nerves.
  • Adult P0a-Cre+Nf1(fl/-) mice developed neurofibromas, and Nf1(+/-)Ink4a/Arf(-/-) and Nf1/p53(+/-) mice developed MPNSTs, but NCSCs did not persist postnatally in affected locations in these mice.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6;129S2-Trp53<tm1Tyj> Nf1<tm1Tyj>/J (subscription/membership/fee required).
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129S2-Nf1<tm1Tyj>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Dec 10;286(5447):2172-6 [10591652.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):117-28 [18242512.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Genes Dev. 2001 Apr 1;15(7):859-76 [11297510.001]
  • [Cites] Histopathology. 2001 Sep;39(3):298-309 [11532041.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):86-91 [11544531.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4978-82 [12118376.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):643-56 [12194865.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):657-69 [12194866.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):75-9 [12469121.001]
  • [Cites] Neuron. 2003 Apr 10;38(1):17-31 [12691661.001]
  • [Cites] Science. 2003 Aug 15;301(5635):972-6 [12920301.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Mol Cancer. 2004 Jul 15;3:20 [15255999.001]
  • [Cites] Nat Neurosci. 2004 Sep;7(9):930-8 [15322547.001]
  • [Cites] Development. 2004 Nov;131(22):5599-612 [15496445.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5435-9 [2142531.001]
  • [Cites] Development. 1990 May;109(1):91-103 [2209471.001]
  • [Cites] Histopathology. 1991 Jul;19(1):1-11 [1916682.001]
  • [Cites] Cell. 1992 Dec 11;71(6):973-85 [1458542.001]
  • [Cites] Nat Genet. 1994 Jul;7(3):353-61 [7920653.001]
  • [Cites] Genes Dev. 1994 May 1;8(9):1019-29 [7926784.001]
  • [Cites] Nature. 1994 Oct 27;371(6500):796-9 [7935840.001]
  • [Cites] Oncogene. 1995 Jul 20;11(2):325-35 [7624147.001]
  • [Cites] Cell. 1995 Sep 8;82(5):733-42 [7671302.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Mol Cell Neurosci. 1997;8(5):336-50 [9073396.001]
  • [Cites] Curr Biol. 1998 Dec 3;8(24):1323-6 [9843687.001]
  • [Cites] Cell. 1999 Mar 5;96(5):737-49 [10089888.001]
  • [Cites] Development. 1999 Sep;126(17):3781-94 [10433908.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1082-93 [15517002.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):74-81 [15715087.001]
  • [Cites] J Neurosci. 2005 Jun 8;25(23):5584-94 [15944386.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):557-64 [16069817.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Nat Rev Neurosci. 2005 Sep;6(9):671-82 [16136171.001]
  • [Cites] Development. 2005 Dec;132(24):5577-88 [16314489.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1005-15 [17158956.001]
  • [Cites] Dev Biol. 2007 Jul 15;307(2):340-55 [17540359.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2176-9 [10591653.001]
  • (PMID = 18242513.001).
  • [ISSN] 1535-6108
  • [Journal-full-title] Cancer cell
  • [ISO-abbreviation] Cancer Cell
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL077342-04; United States / NINDS NIH HHS / NS / R01 NS040750; United States / NINDS NIH HHS / NS / R01 NS040750-06; United States / NINDS NIH HHS / NS / NS040750-08; United States / NINDS NIH HHS / NS / NS040750-07; United States / NINDS NIH HHS / NS / R01 NS040750-01; United States / NINDS NIH HHS / NS / R01 NS40750; United States / NINDS NIH HHS / NS / R01 NS040750-08; United States / NINDS NIH HHS / NS / NS040750-06; United States / NINDS NIH HHS / NS / R01 NS040750-07; United States / NHLBI NIH HHS / HL / R01 HL077342; United States / NHLBI NIH HHS / HL / T32 HL079995; United States / NHLBI NIH HHS / HL / HL077342-04; United States / NINDS NIH HHS / NS / NS040750-01; United States / NINDS NIH HHS / NS / F30 NS049761
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS40133; NLM/ PMC2566828
  •  go-up   go-down


60. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Iwamoto Y, Tsuneyoshi M: Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol; 2006 Apr;19(4):524-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CHFR in malignant peripheral nerve sheath tumors.
  • In MPNST, complex karyotypes showing numerical and structural aberrations have been described.
  • We examined the expression of CHFR in 96 cases of MPNST by immunohistochemical and molecular methods.
  • We found reduced (score, < or = 3) expression of CHFR in 63 out of 96 (66%) cases of MPNST, and such alteration was significantly correlated with a high mitotic count, a high Ki-67-labeling index, and a poor prognosis.
  • In addition, MPNST with normal karyotype showed a strong (score, =5) expression of CHFR.
  • Our results support the assertion that CHFR functions as an inhibitor of tumor proliferation.
  • [MeSH-major] Cell Cycle Proteins / genetics. Neoplasm Proteins / genetics. Nerve Sheath Neoplasms / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / analysis. Male. Middle Aged. Multivariate Analysis. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554732.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


61. Otsuka H, Graham MM, Kubo A, Nishitani H: FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report. Ann Nucl Med; 2005 Feb;19(1):55-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • About 5% of patients with NF-1 develop sarcomatous transformation of a malignant peripheral nerve sheath tumor which arises from plexiform neurofibromas and is often associated with a poor prognosis.
  • Morphologic imaging techniques such as Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) are the standard methods to define the anatomic extent of the tumor, although tumor heterogeneity prevents reliable differentiation between benign and malignant lesions.
  • The degree of fluoro-deoxyglucose (FDG) uptake correlates with histologic grade in neurogenic tumors in NF-1 patients.
  • Our patient had a huge mass in the left gluteus area with a large nearly circular focus of increased FDG uptake in the tumor.
  • We surmised that the high FDG uptake indicated a high grade sarcoma, which was confirmed histologically.
  • FDG-PET/CT can identify sarcomatous change from benign neurogenic tumor with minimal misregistration, and can also detect metastatic disease.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Fluorodeoxyglucose F18. Neurofibromatoses / radiography. Neurofibromatoses / radionuclide imaging. Sarcoma / radiography. Sarcoma / radionuclide imaging. Subtraction Technique
  • [MeSH-minor] Adult. Humans. Male. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770975.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Dartnell J, Pilling J, Ferner R, Cane P, Lang-Lazdunski L: Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor. J Thorac Oncol; 2009 Jan;4(1):135-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant triton tumor of the brachial plexus invading the left thoracic inlet: a rare differential diagnosis of pancoast tumor.
  • Malignant triton tumor is a divergent malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation.
  • We report a case of malignant triton tumor arising in the brachial plexus of a 28-year-old women with neurofibromatosis type 1.
  • Fluorodeoxyglucose-positron emission tomography-computed tomography before excision demonstrated a tumor with a maximum standard uptake value of 21 at 4 hours postinjection.
  • The patient underwent complete excision of the tumor through median sternotomy and left supraclavicular approach.
  • [MeSH-major] Brachial Plexus / pathology. Neurilemmoma / diagnosis. Pancoast Syndrome / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neurofibromatosis 1 / complications. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096322.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


63. Baek WS, Pytel P, Undevia SD, Rubeiz H: Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor. J Neurooncol; 2005 Sep;74(2):183-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
  • Malignant peripheral nerve sheath tumors are rare spindle-cell sarcomas derived from Schwann cells or pluripotent cells of the neural crest.
  • They arise from the spinal roots, peripheral nerves, brachial and lumbosacral plexi, cranial nerves and terminal nerve fibers within soft tissue, intestine, lung and bone.
  • Spinal cord metastasis from malignant nerve sheath tumors associated with neurofibromatosis type 1 is very rare.
  • We describe a rare case of near-total spinal cord metastasis in a patient with malignant nerve sheath tumor in the absence of neurofibromatosis, and highlight the microscopic findings and natural history of this disease process.
  • [MeSH-major] Lung Neoplasms / secondary. Nerve Sheath Neoplasms / pathology. Neurofibroma / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Benzenesulfonates / therapeutic use. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / therapeutic use


64. Wasa J, Nishida Y, Tsukushi S, Shido Y, Sugiura H, Nakashima H, Ishiguro N: MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol; 2010 Jun;194(6):1568-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas.
  • OBJECTIVE: The objective of this study was to identify the MRI criteria that best differentiate malignant peripheral nerve sheath tumors from benign neurofibromas.
  • MATERIALS AND METHODS: We retrospectively analyzed MR images obtained for 41 histologically diagnosed cases of malignant peripheral nerve sheath tumor and 20 cases of neurofibroma that had been treated at four tertiary institutions.
  • Twenty of the patients with malignant peripheral nerve sheath tumors and 14 patients with neurofibromas developed the disease in association with neurofibromatosis 1.
  • The MR images were evaluated with regard to tumor size, signal intensity, heterogeneity of T1- and T2-weighted MR images, enhancement pattern, definition of margins, presence of perilesional edemalike zone, and presence of intratumoral cystic lesions.
  • RESULTS: Significant differences between malignant peripheral nerve sheath tumors and neurofibromas were noted for the largest dimension of the mass, peripheral enhancement pattern, perilesional edemalike zone, and intratumoral cystic lesion.
  • In cases associated with neurofibromatosis 1, heterogenicity on T1-weighted images was also significant in differentiating neurofibroma from malignant peripheral nerve sheath tumor.
  • The presence of two or more of the four features suggestive of malignancy indicated malignant peripheral nerve sheath tumor with a sensitivity of 61% and a specificity of 90%.
  • CONCLUSION: The MR features described in this study are useful for distinguishing malignant peripheral nerve sheath tumors from neurofibromas.
  • If a tumor has two or more of the four statistically significant features, it can be considered to be highly suspicious of malignancy and should be subjected to a biopsy for early diagnosis.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Nerve Sheath Neoplasms / diagnosis. Neurofibromatosis 1 / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neurofibroma / diagnosis. Neurofibroma / pathology. Retrospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489098.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


65. Chirife AM, Bello L, Celeste F, Giménez L, Gorostidy S: [Primary sarcomas of the breast]. Medicina (B Aires); 2006;66(2):135-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sarcomas of the breast are extremely rare with less than 1% of all malignant tumours of the breast reported in literature.
  • At our Institution 1315 malignant tumours of the breast were diagnosed between 1999-2004; nine of them corresponded to primary sarcomas: angiosarcoma (3), leiomyosarcoma (1), low-grade fibromyxoid sarcoma (1), dematofibrosarcoma protuberans (1), liposarcoma (1), osteosarcoma (1), malignant peripheral nerve sheath tumour (1).
  • Most of the tumours (67%) showed p53 (mayor or equal to 20% of nuclear staining) over-expression but this did not show a direct relationship with the evolution of each neoplasm.
  • [MeSH-major] Breast Neoplasms. Sarcoma
  • [MeSH-minor] Adult. Argentina / epidemiology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Humans. Incidence. Middle Aged. Phenotype. Prevalence. Prognosis. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


66. Luna-Ortiz K, Navarrete-Alemán JE, Granados-García M, Herrera-Gómez A: Primary parapharyngeal space tumors in a Mexican cancer center. Otolaryngol Head Neck Surg; 2005 Apr;132(4):587-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixteen (76%) patients had benign lesions and 5 (24%) had malignant tumors.
  • Neurogenic tumors represented 57% of all tumors.
  • Mean tumor size was of 6.7 cm (range, 3 to 11 cm).
  • Complications occurred in 6 (29%) patients, 4 (19%) of which were nervous injuries associated with peripheral nerve sheath tumors.
  • Conversion to mandibular swing approach when the cervical approach is not offering proper exposure for tumor resection is indicated.
  • Nevertheless, CT scan should always be performed in order to exclude paragangliomas, distinguish prestyloid from poststyloid lesions, and to assess the extension of the tumor as well as its relationship with adjacent structures.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Neurilemmoma / diagnosis. Pharyngeal Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / mortality. Adenoma, Pleomorphic / pathology. Adenoma, Pleomorphic / radiotherapy. Adenoma, Pleomorphic / surgery. Adult. Aged. Biopsy, Fine-Needle. Cancer Care Facilities. Cervical Vertebrae / surgery. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Laminectomy. Magnetic Resonance Imaging. Male. Mexico. Middle Aged. Parotid Gland / pathology. Parotid Gland / surgery. Pharyngectomy / methods. Pharynx / pathology. Postoperative Complications / etiology. Postoperative Complications / mortality. Radiotherapy, Adjuvant. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806051.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Hemalatha AL, Karthikeyan TM, Bharatnur SS, Kumar AS: Malignant peripheral nerve sheath tumor in oral cavity--a rare site. Indian J Pathol Microbiol; 2006 Jul;49(3):397-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor in oral cavity--a rare site.
  • MPNST occurring in oral cavity, which is a rare site for the tumour, in a 35 year old female patient with history of swelling underneath the tongue present since one year diagnosed clinically as ranula is presented here.
  • Histopathological examination of the excised mass showed features of spindle cell sarcoma following which a provisional diagnosis of MPNST was offered.
  • [MeSH-major] Mouth / pathology. Mouth Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001897.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


68. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, Tamiya S, Yamada T, Oda S, Tanaka K, Matsuda S, Iwamoto Y, Tsuneyoshi M: Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients. Cancer Genet Cytogenet; 2006 Mar;165(2):98-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal aberrations and microsatellite instability of malignant peripheral nerve sheath tumors: a study of 10 tumors from nine patients.
  • Malignant peripheral nerve sheath tumor (MPNST) is an uncommon soft tissue neoplasm with a poor prognosis, occurring sporadically or associated with neurofibromatosis type 1 (NF1); however, the histogenesis of MPNST remains unclear, especially in sporadic tumors.
  • To elucidate the chromosomal aberration as a consequence of CIN and MSI status of MPNST, we karyotyped 10 MPNSTs from nine patients, and examined the MSI of seven microsatellite markers using high-resolution fluorescence microsatellite analysis; 2 out of 10 cases (20%) had normal karyotypes, and 8 out of 10 cases (80%) revealed structural and numerical chromosomal aberrations.
  • These findings suggest that chromosomal aberration as a consequence of CIN has a greater role in the pathogenesis of MPNST than does that due to MSI.
  • [MeSH-major] Chromosome Aberrations. Microsatellite Repeats / genetics. Nerve Sheath Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Karyotyping. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527603.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


69. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • Liposarcoma and malignant fibrous histiocytoma were the most often diagnosed subgroups at 24% and 22.6%, respectively.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y, Yamashita T, Chuman H, Beppu Y, Tani Y, Hasegawa T: Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer; 2005 May 1;103(9):1881-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
  • BACKGROUND: Little is known about the expression of receptor tyrosine kinases in adult soft tissue sarcomas (STS).
  • METHODS: The current study included 281 adult patients with STS of the extremity and trunk who were diagnosed and treated in the National Cancer Center, Tokyo.
  • Positive staining was common in pleomorphic malignant fibrous histiocytomas (89%), myxofibrosarcomas (89%), synovial sarcomas (76%), malignant peripheral nerve sheath tumors (89%), and leiomyosarcomas (73%).
  • CONCLUSIONS: EGFR overexpression was found to be a negative prognostic factor of adult STS, which is strongly associated with histologic grade.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Adult. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Paraffin Embedding. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15772959.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


71. Maire JP, Huchet A, Milbeo Y, Darrouzet V, Causse N, Célérier D, Liguoro D, Bébéar JP: Twenty years' experience in the treatment of acoustic neuromas with fractionated radiotherapy: a review of 45 cases. Int J Radiat Oncol Biol Phys; 2006 Sep 1;66(1):170-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median tumor diameter was 31 mm (range, 11-55 mm).
  • Tumor shrinkage was observed in 27 (59%) and stable disease in 16 (35%).
  • Tumor progression occurred in three patients, 12 to 15 months after FRT.
  • Actuarial local tumor control rates at 5 and 15 years were 86%.
  • For the patient who had a tumor recurrence at 216 months, histologic examination documented transformation to a low-grade malignant peripheral nerve sheath tumor.
  • However, our results suggest that malignant transformation can occur many years after FRT so we advocate caution when using this treatment for young patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Dose Fractionation. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904521.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Okoshi A, Shiga K, Sasaki K, Asada Y, Nishikawa H, Kobayashi T, Watanabe M: [Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):533-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of radiation-induced sarcoma after radiation therapy in nasopharyngeal carcinoma].
  • We report two cases of radiation-induced sarcoma after chemoradiation therapy in nasopharyngeal carcinoma.
  • Case 1: A 40-year-old man developed a malignant peripheral nerve sheath tumor (MPNST) in the posterior floor of the nasal cavity 10 years after treatment for nasopharyngeal cancer.
  • Case 2: A 64 year-old man developed a malignant fibrous histiocytoma (MFH) of the lower gum 10 years after treatment of nasopharyngeal cancer.
  • Despite radical surgery, the man with MPNST had a recurrent tumor and died of the disease.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / etiology. Nasopharyngeal Neoplasms / etiology. Neoplasms, Radiation-Induced / etiology. Nerve Sheath Neoplasms / etiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697477.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


73. Kushida Y, Haba R, Kobayashi S, Ishikawa M, Doi T, Kadota K: Ectopic hamartomatous thymoma: a case report with immunohistochemical study and review of the literature. J Cutan Pathol; 2006 May;33(5):369-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ectopic hamartomatous thymoma (EHT) is a rare benign tumor.
  • The tumor consisted of spindle cells, epithelial cells, adipose cells, and a small amount of lymphocytes, as described previously.
  • Recognition of EHT is important and needs to be differentiated from high-grade sarcomas such as synovial sarcoma or glandular malignant peripheral nerve sheath tumor.
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD1 / metabolism. Antigens, CD20 / metabolism. Antigens, CD34 / metabolism. Antigens, CD45 / metabolism. Cell Adhesion Molecules / metabolism. Diagnosis, Differential. Humans. Keratins / metabolism. Male. Nerve Sheath Neoplasms / pathology. Sarcoma, Synovial / metabolism. Sarcoma, Synovial / pathology. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640545.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / Antigens, CD20; 0 / Antigens, CD34; 0 / CD1a antigen; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Vimentin; 68238-35-7 / Keratins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


74. Stark AM, Mehdorn HM: Multiple intracranial metastases from a malignant peripheral nerve sheath tumor of the extremities. J Neurooncol; 2006 Jun;78(2):209-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple intracranial metastases from a malignant peripheral nerve sheath tumor of the extremities.
  • [MeSH-major] Brain Neoplasms / secondary. Lung Neoplasms / secondary. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Growth Hormone / metabolism. Humans. Male. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology. Thigh. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2001;143(4):357-63; discussion 363-4 [11437289.001]
  • [Cites] Neurology. 2003 Sep 9;61(5):696-8 [12963767.001]
  • [Cites] Folia Neuropathol. 2004;42(1):43-8 [15119745.001]
  • [Cites] Gen Diagn Pathol. 1997 Jun;142(5-6):357-60 [9228261.001]
  • (PMID = 16598432.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


75. Perrin GQ, Fishbein L, Thomson SA, Thomas SL, Stephens K, Garbern JY, DeVries GH, Yachnis AT, Wallace MR, Muir D: Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line. J Neurosci Res; 2007 May 1;85(6):1347-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform-like neurofibromas develop in the mouse by intraneural xenograft of an NF1 tumor-derived Schwann cell line.
  • Plexiform neurofibromas are peripheral nerve sheath tumors that arise frequently in neurofibromatosis type 1 (NF1) and have a risk of malignant progression.
  • Past efforts to establish xenograft models for neurofibroma involved the implantation of tumor fragments or heterogeneous primary cultures, which rarely achieved significant tumor growth.
  • We report a practical and reproducible animal model of plexiform-like neurofibroma by xenograft of an immortal human NF1 tumor-derived Schwann cell line into the peripheral nerve of scid mice.
  • Localized intraneural injection of the cell line sNF94.3 produced consistent and slow growing tumors that infiltrated and disrupted the host nerve.
  • [MeSH-major] Cell Line, Tumor. Lung Neoplasms / pathology. Neurofibromatosis 1 / pathology. Schwann Cells / cytology
  • [MeSH-minor] Adult. Animals. Blotting, Western. Female. Humans. Mice. Mice, SCID. Neoplasm Transplantation / methods. Nerve Tissue Proteins / metabolism. Neurofibromin 1 / genetics. Transplantation, Heterologous / methods. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17335073.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32-CA09126-27
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Neurofibromin 1; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


76. Kang GH, Kim KM, Noh JH, Sohn TS, Kim S, Park CK, Lee CS, Kang DY: WT-1 expression in gastrointestinal stromal tumours. Pathology; 2010 Jan;42(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyosarcomas, schwannomas, malignant peripheral nerve sheath tumours (MPNSTs) and melanomas showed cytoplasmic staining, whereas leiomyomas and mesenteric fibromatoses were totally negative for WT-1.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastrointestinal Stromal Tumors / metabolism. Soft Tissue Neoplasms / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Receptor, Platelet-Derived Growth Factor alpha / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20025481.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


77. Melliou A, Karamouzis J, Helis L, Mouzakiti A, Theocharidis G, Karkavelas G, Kouroussis C: Malignant peripheral nerve-sheath tumor of the left cerebello-pontine angle: case report. J BUON; 2006 Jul-Sep;11(3):367-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve-sheath tumor of the left cerebello-pontine angle: case report.
  • [MeSH-major] Cerebellar Neoplasms. Cerebellopontine Angle. Nerve Sheath Neoplasms
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309166.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


78. Bahrami A, Folpe AL: Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period. Am J Surg Pathol; 2010 Oct;34(10):1504-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period.
  • Adult-type fibrosarcoma (FS) was once considered the most common adult sarcoma, but is now considered a diagnosis of exclusion.
  • One hundred ninety-five cases diagnosed as adult FS in somatic soft tissue were retrieved from our institutional archives for the period 1960 to 2008.
  • Non-FS (137 cases) were reclassified as: undifferentiated pleomorphic sarcoma (32 cases), SS (21 cases), solitary fibrous tumor (14 cases), myxofibrosarcoma (11 cases), malignant peripheral nerve sheath tumor (8 cases), FS dermatofibrosarcoma protuberans, and desmoplastic melanoma (4 cases each), low-grade fibromyxoid sarcoma, sarcomatoid carcinoma, desmoid-type fibromatosis, rhabdomyosarcoma, myofibroblastic sarcoma, spindle-cell liposarcoma (3 cases each), sclerosing epithelioid FS, fibroma-like epithelioid sarcoma, leiomyosarcoma, cellular fibrous histiocytoma (2 cases each), and others (17 cases).
  • Exclusive of undifferentiated pleomorphic sarcoma, the distinction of which from FS is subjective, 64% of putative FS were reclassified, most commonly as monophasic SS and solitary fibrous tumor.
  • We conclude that true FS is exceedingly rare, accounting for <1% of approximately 10,000 adult soft tissue sarcomas seen at our institution during this time period, and should be diagnosed with great caution.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Child, Preschool. DNA, Neoplasm / analysis. Female. Gene Rearrangement. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Minnesota / epidemiology. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Repressor Proteins / genetics. Repressor Proteins / metabolism. Young Adult


79. Santaella Y, Borrego I, López J, Ortiz MJ, Vázquez R: [18-FDG-PET in a case of recurrent malignant schwannoma]. Rev Esp Med Nucl; 2005 Mar-Apr;24(2):127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [18-FDG-PET in a case of recurrent malignant schwannoma].
  • [Transliterated title] Diagnóstico de recurrencia mediante FDG-PET en un caso clínico de schwannoma maligno.
  • The peripheral nerve sarcoma, also called malignant schwannoma, is originally a soft tissue sarcoma.
  • It is mainly located in the peripheral sheath nerve of the limbs and usually infiltrates the nerve fibres.
  • We present the case of a thirty year old woman with a malignant schwannoma in her left leg sciatic nerve who had been treated on several occasions.
  • PET can be a useful technique to detect recurrence for this kind of tumor, mainly in patients who have been previously radiated when the MRI is insufficient to perform a differential diagnosis between postirradiation fibrosis and tumoral recurrence, allowing for suitable therapeutic management of the patient.
  • [MeSH-major] Fluorodeoxyglucose F18. Neurilemmoma / radionuclide imaging. Peripheral Nervous System Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Sciatic Neuropathy / radionuclide imaging
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15745683.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


80. Allison KH, Patel RM, Goldblum JR, Rubin BP: Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis. Am J Clin Pathol; 2005 Nov;124(5):685-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis.
  • We reviewed the clinicopathologic features of 5 cases of malignant peripheral nerve sheath tumor (MPNST) manifesting in superficial locations associated with cutaneous neurofibromas (4 cases) or superficial peripheral nerve (1 case).
  • However, identification of a benign precursor or origin from a nerve may be the most definitive way to properly classify these rare lesions.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. S100 Proteins / analysis

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203275.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


81. Scheithauer BW, Erdogan S, Rodriguez FJ, Burger PC, Woodruff JM, Kros JM, Gokden M, Spinner RJ: Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. Am J Surg Pathol; 2009 Mar;33(3):325-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases.
  • Malignant peripheral nerve sheath tumors (MPNSTs) arising from cranial nerves or their branches are very uncommon.
  • In addition, 1 tumor involved the optic chiasm (n=1).
  • Only 1 tumor arose in brain parenchyma of (frontal lobe).
  • One patient with a vestibular tumor and presumed NF2 had previously undergone resection of a contralateral vestibular cellular schwannoma.
  • One posterior fossa tumor was a malignant melanotic schwannoma.
  • Four patients had postirradiation malignant peripheral nerve sheath tumors, 2 having been treated for optic chiasm glioma, both being NF1 affected.
  • Identifiable precursor lesions included schwannoma (n=4), plexiform neurofibroma (n=2), and solitary intraneural neurofibroma (n=2).
  • Malignant cranial nerve sheath tumors are rare and are associated with the same poor prognosis as those of spinal nerves at other sites.
  • [MeSH-major] Brain Neoplasms / pathology. Cranial Nerve Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065105.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Karatzoglou P, Karagiannidis A, Kountouras J, Christofiridis CV, Karavalaki M, Zavos C, Gavalas E, Patsiaoura K, Vougiouklis N: Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature. Anticancer Res; 2008 Sep-Oct;28(5B):3107-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Von Recklinghausen's disease associated with malignant peripheral nerve sheath thmor presenting with constipation and urinary retention: a case report and review of the literature.
  • A malignant peripheral nerve sheath tumor (MPNST) is a rare neoplasm arising from peripheral nerve sheaths.
  • We herein report the first case of MPNST originating from the left gluteal muscle region, diffusely extending into the adjacent small pelvis and perineum.
  • A computed tomography scan revealed a giant tumor which displaced the bladder and segments of the intestine.
  • The histopathological diagnosis was MPNST.
  • [MeSH-major] Constipation / etiology. Nerve Sheath Neoplasms / complications. Neurofibromatosis 1 / complications. Urinary Retention / etiology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19031965.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


83. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, Randlev B, Wang Q, Freeman S, Rubin J: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther; 2005 Mar;12(5):437-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We, therefore, undertook a phase I/II study of ONYX-015, days 1-5 every month administered intratumorally under radiographic guidance, in combination with MAP (mitomycin-C, doxorubicin, cisplatin) chemotherapy in patients with advanced sarcoma.
  • Sarcoma histologies were gastrointestinal stromal tumors (GIST, two patients), leiomyosarcoma (two patients), liposarcoma (one patient), and malignant peripheral nerve sheath tumor (1 patient).
  • ONYX-015 viral DNA was detected by quantitative PCR in the plasma of 5/6 patients on day 5 of the first cycle, and up to day 12 (7 days after the last viral dose) in one patient who had extended sampling for viral kinetics performed, suggesting viral replication in sarcoma tissue.
  • Detection of viral DNA in post treatment tumor specimens by ISH and detection of the ONYX-015 genome in the peripheral blood by quantitative PCR, up to 7 days after the last viral dose provide evidence for adenoviral replication.
  • [MeSH-major] Adenoviridae. Antineoplastic Agents / administration & dosage. Genetic Therapy / methods. Sarcoma / therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Viral / blood. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. DNA, Viral / analysis. DNA, Viral / blood. Doxorubicin / administration & dosage. Female. Humans. In Situ Hybridization. Injections, Intralesional. Male. Middle Aged. Mitomycin / administration & dosage. Viral Vaccines. Virus Replication

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647767.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 84388; United States / NCI NIH HHS / CA / U01CA 69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antineoplastic Agents; 0 / DNA, Viral; 0 / ONYX015; 0 / Viral Vaccines; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; MAP protocol
  •  go-up   go-down


84. Lee CC, Yen YS, Pan DH, Chung WY, Wu HM, Guo WY, Chen MT, Liu KD, Shih YH: Delayed microsurgery for vestibular schwannoma after gamma knife radiosurgery. J Neurooncol; 2010 Jun;98(2):203-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed microsurgery for vestibular schwannoma after gamma knife radiosurgery.
  • However, on rare occasions, some cases have needed traditional microsurgery to remove the tumor several months or years after radiosurgery.
  • The mean size of the tumor during GKS was 10.4 ml (range 2.3-23.5 ml).
  • The indications of microsurgery included adverse radiation effect with peri-focal edema, tumor enlargement, and cyst enlargement.
  • Although the perifocal edema could lead to more difficulty in surgery than in typically performed operations for schwannoma, subtotal resection was achieved in all patients.
  • The histology showed benign tumor in five patients, malignant peripheral nerve sheath tumor in one, and necrotic tissue in one.
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted / methods. Ki-67 Antigen / metabolism. Longitudinal Studies. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. S100 Proteins / metabolism. Severity of Illness Index. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2007 Mar;149(3):313-6; discussion 316-7 [17273886.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] J Neurosurg. 2006 Oct;105(4):576-80 [17044561.001]
  • [Cites] J Neurosurg. 1992 May;76(5):874-7 [1564550.001]
  • [Cites] J Neurosurg. 1990 Dec;73(6):946-50 [2230979.001]
  • [Cites] J Korean Med Sci. 2001 Dec;16(6):817-21 [11748371.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):671-6; discussion 676-7 [12181700.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):469-81; discussion 481-2 [9055285.001]
  • [Cites] Am J Surg Pathol. 2009 Mar;33(3):325-38 [19065105.001]
  • [Cites] Acta Otolaryngol Suppl. 2000;543:11-3 [10908962.001]
  • [Cites] Acta Neuropathol. 1987;74(1):92-6 [3499046.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:103-11 [9032850.001]
  • [Cites] J Laryngol Otol. 2000 Dec;114(12):935-9 [11177361.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):653-8 [9761063.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):908-12 [12810777.001]
  • [Cites] Neurosurgery. 2008 May;62(5):E1164-5; discussion E1165 [18580785.001]
  • [Cites] Am J Otol. 1995 May;16(3):315-9; discussion 319-21 [8588625.001]
  • [Cites] Arch Pathol Lab Med. 1983 Jun;107(6):293-7 [6687792.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):7-13 [11147901.001]
  • [Cites] Cancer. 2005 Aug 1;104(3):580-90 [15952200.001]
  • [Cites] J Neurosurg. 2000 May;92(5):745-59 [10794287.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(6):695-9 [8836284.001]
  • [Cites] J Laryngol Otol. 1994 May;108(5):375-9 [8035113.001]
  • [Cites] N Engl J Med. 1998 Nov 12;339(20):1426-33 [9811917.001]
  • [Cites] Clin Neurosurg. 1993;40:498-535 [8111998.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):949-55 [9833821.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):422-5 [1993907.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):87-97 [28306447.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • (PMID = 20405307.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


85. Ziadi A, Saliba I: Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review. Auris Nasus Larynx; 2010 Oct;37(5):539-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.
  • OBJECTIVES: The incidence of malignant peripheral nerve sheath tumor (MPNST) is approximately 0.001%.
  • (1) to review all cases of intracranial MPNST described in the literature, (2) to highlight the suspicion of intracranial MPNST, (3) to identify the gross pathology, the histopathology, the immunohistochemistry, (4) to discuss the differential diagnosis, the treatment, the recurrence rate, the follow-up, the incidence of metastasis and the prognosis.
  • We used the following Keywords: "malignant peripheral nerve sheath tumor", "cranial nerve", "neurosarcoma", "malignant schwannoma", "neurofibroma", "malignant neurofibroma" and "nerve tumor".
  • We considered cases where MPNST involved an intracranial cranial nerve.
  • RESULTS: We identified 32 cases of cranial MPNST including our case.
  • Most cases are developed sporadically (50%), 31% arise from a malignant transformation of schwannoma and 19% from a neurofibroma.
  • The cranial nerve VIII is the most involved (15/32), followed by the Vth (10/32) and the VIIth (5/32).
  • MPNST will strongly express protein S-100 and collagen IV-laminin.
  • 13 cases were treated with radiotherapy for tumor recurrence and metastasis.
  • CONCLUSION: MPNST of cranial nerves are very rare.
  • In neurofibroma, even though MPNST is mainly associated to type 1, we should keep in mind its association to NF2.
  • Inaccessibility of cranial MPNST may explain the subtotal resection and thus the poor prognosis.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Nerve Sheath Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Transformation, Neoplastic / pathology. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neurilemmoma / diagnosis. Neurilemmoma / pathology. Neurilemmoma / radiotherapy. Neurilemmoma / surgery. Neurofibroma / diagnosis. Neurofibroma / pathology. Neurofibroma / radiotherapy. Neurofibroma / surgery. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / pathology. Neurofibromatosis 1 / radiotherapy. Neurofibromatosis 1 / surgery. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / pathology. Neurofibromatosis 2 / radiotherapy. Neurofibromatosis 2 / surgery. Radiotherapy, Adjuvant. Spinal Neoplasms / mortality. Spinal Neoplasms / pathology. Spinal Neoplasms / secondary. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399579.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


86. Santarius T, Chia HL, Xuereb JH, Kirollos RW: Sporadic malignant nerve sheath tumour of the oculomotor nerve. Acta Neurochir (Wien); 2007 Jun;149(6):617-22; discussion 622
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic malignant nerve sheath tumour of the oculomotor nerve.
  • Malignant peripheral nerve sheath tumours (MPNST) are exceedingly rare in an intracranial location.
  • In this report clinical and pathological evidence for the diagnosis of a MPNST arising from of the oclumotor nerve is presented.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Oculomotor Nerve Diseases / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Decompression, Surgical. Diagnosis, Differential. Diplopia / etiology. Female. Headache / etiology. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Microsurgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / diagnosis. Neoplasm, Residual / surgery. Ophthalmoplegia / etiology. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Radiosurgery. Reoperation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17514351.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Jokinen CH, Argenyi ZB: Atypical neurofibroma of the skin and subcutaneous tissue: clinicopathologic analysis of 11 cases. J Cutan Pathol; 2010 Jan;37(1):35-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neurofibroma (NF) is a relatively common cutaneous tumor, which typically presents little diagnostic difficulty.
  • Occasionally, however, pleomorphic cells may be present in NF raising consideration of other neoplasms like malignant peripheral nerve sheath tumor (MPNST).
  • Some tumors were hypercellular, but marked density characteristic of MPNST was not observed.
  • Of six patients with available follow-up, no tumor recurred and none developed malignancy (range 6-63, mean 33 months).
  • CONCLUSIONS: Superficial atypical NF, while morphologically unusual, has no apparent association with neurofibromatosis-1 or short-term risk of recurrence or malignant transformation.
  • Awareness of this variant is important in order to avoid misdiagnosis of a more aggressive neoplasm.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Nerve Sheath Neoplasms / pathology. S100 Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Neurofibroma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 19469864.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


88. Albayrak BS, Gorgulu A, Kose T: A case of intra-dural malignant peripheral nerve sheath tumor in thoracic spine associated with neurofibromatosis type 1. J Neurooncol; 2006 Jun;78(2):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intra-dural malignant peripheral nerve sheath tumor in thoracic spine associated with neurofibromatosis type 1.
  • Histopathological diagnosis was malignant peripheral nerve sheath tumor (MPNST), a rare sarcoma with a dismal prognosis.
  • Tumor recurred in its previous site with an adjacent apical mass in the left lung 7 weeks following initial surgery and repeat surgery was performed with complete removal of intra-dural tumor.
  • We report the first patient with intra-dural MPNST localized proximal to conus medullaris; in upper thoracic spine.
  • It must always be considered the possibility of a rare but a devastating tumor, MPNST beside schwannomas and neurofibromas in patients with NF1 when an intra-spinal mass is diagnosed.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Neurofibromatosis 1 / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Dura Mater / pathology. Humans. Male. Neoplasm Recurrence, Local / surgery. Thoracic Vertebrae. Treatment Outcome


89. Dang JD, Cohen PR: Segmental neurofibromatosis and malignancy. Skinmed; 2010 May-Jun;8(3):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The malignancies include malignant peripheral nerve sheath tumor (3), malignant melanoma (2), breast cancer (1), colon cancer (1), gastric cancer (1), lung cancer (1), and Hodgkin lymphoma (1).
  • The most common malignancies in patients with segmental neurofibromatosis are derived from neural crest cells: malignant peripheral nerve sheath tumor and malignant melanoma.
  • [MeSH-minor] Adult. Aged. Cafe-au-Lait Spots / etiology. Cafe-au-Lait Spots / pathology. Female. Humans. Incidence. Male. Middle Aged. Neural Crest / cytology. Neural Crest / pathology. Risk

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137621.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


90. Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, Brennan MF, Singer S: Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol; 2010 Apr 20;28(12):2064-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A matched-cohort analysis was performed for radiation-associated and sporadic malignant fibrous histiocytoma (MFH).
  • DSS was significantly worse in primary RAS malignant peripheral nerve sheath tumors (MPNSTs) compared with unmatched sporadic MPNSTs (P = .001).
  • CONCLUSION Histologic type, margin status, and tumor size are the most important independent predictors of DSS in patients with RASs.
  • DSS in patients with primary RAS is significantly worse compared with sporadic STS independent of sarcoma histologic type.


91. Izycka-Swieszewska E, Drogoszewska B, Filipowicz J, Szurowska E, Kaminski M, Jaskiewicz K: Epithelioid malignant peripheral nerve sheath tumor involving maxillary sinus. Neuropathology; 2005 Dec;25(4):341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid malignant peripheral nerve sheath tumor involving maxillary sinus.
  • We present a case of epithelioid malignant peripheral nerve sheath tumor (MPNST) located in the maxillary sinus region in a young man.
  • Histologically, the neoplasm had a predominant epithelioid component.
  • An appropriate immunohistochemical panel was essential for the final diagnosis of this epithelioid malignant tumor, with the location rather unusual for MPNST.
  • [MeSH-major] Maxillary Sinus Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma / pathology. Diagnosis, Differential. Fatal Outcome. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382783.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


92. Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H: Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest; 2007 Aug;87(8):767-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
  • Malignant peripheral nerve sheath tumor (MPNST) is rare, highly aggressive, resistant to radiochemotherapy, and associated with poor prognosis.
  • This study was designed to identify motogenic factor(s) involved in MPNST cell invasion and inhibitor(s) of such invasive activity.
  • We profiled the invasion-inducing activities of eight motogenic growth factors on two human MPNST cell lines, FU-SFT8611 and 9817, using in vitro Matrigel invasion assays.
  • Platelet-derived growth factor-BB (PDGF-BB) was identified as the most effective MPNST cell invasion-inducing factor.
  • Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) also stimulated invasion in one MPNST cell line.
  • Expressions of PDGF-BB and EGF receptors (PDGFR-beta and EGFR) mRNAs were detected more frequently and their proteins were expressed at higher levels in MPNST tissues than benign peripheral nerve sheath tumors (schwannomas and neurofibromas).
  • In both MPNST cell lines, PDGF-BB induced tyrosine phosphorylation of PDGFR-beta but not of PDGFR-alpha, and specific PDGFR-beta inhibition by small interfering RNA to the receptor inhibited PDGF-BB-stimulated MPNST cell invasion, suggesting the predominant role of PDGFR-beta.
  • No mutations were present in exons 12 and 18 of PDGFR-beta in both MPNST cell lines and 10 human MPNST tissues examined.
  • Our results indicated that PDGF-BB enhanced the invasive activity of MPNST cells through PDGFR phosphorylation and that imatinib inhibited such activity.
  • The results provide the ground for further assessment of the therapeutic potential of imatinib in suppressing the invasion and growth of MPNST.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Nerve Sheath Neoplasms / metabolism. Piperazines / pharmacology. Platelet-Derived Growth Factor / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Adult. Benzamides. Cell Line, Tumor. Female. Humans. Imatinib Mesylate. Intercellular Signaling Peptides and Proteins / pharmacology. Intercellular Signaling Peptides and Proteins / physiology. Male. Middle Aged. Mutation. Neoplasm Invasiveness. Phosphorylation. Proto-Oncogene Proteins c-sis. RNA, Messenger / metabolism. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Receptor, Platelet-Derived Growth Factor beta / genetics. Receptor, Platelet-Derived Growth Factor beta / metabolism. Receptors, Growth Factor / genetics. Receptors, Growth Factor / metabolism

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558420.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Intercellular Signaling Peptides and Proteins; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / Receptors, Growth Factor; 0 / platelet-derived growth factor BB; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


93. Shintani K, Matsumine A, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Hoki Y, Uchida A: Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch; 2006 Dec;449(6):673-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypoxia-inducible factor (HIF)-1alpha is a transcription factor that supports the adaptation of human cancer cells to hypoxia and tumor growth and progression.
  • The expression of HIF-1alpha protein was immunohistochemically determined in 49 specimens of soft-tissue sarcomas including malignant fibrous histiocytoma (29 patients), synovial sarcoma (12 patients), leiomyosarcoma (four patients), and malignant peripheral nerve sheath tumors (four patients).
  • [MeSH-major] Biomarkers, Tumor / analysis. Hypoxia-Inducible Factor 1, alpha Subunit / analysis. Sarcoma / chemistry
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Prognosis. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1996 Oct;41(1):31-9 [8961365.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Cancer Lett. 2002 Apr 25;178(2):167-74 [11867201.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):260-7 [11314944.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):680-7 [11821448.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):490-7 [9690542.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5328-35 [9393757.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):1005-12 [11251953.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1198-205 [15993027.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):238-44 [9143406.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):172-7 [15677538.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12 ):9519-25 [11120745.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10 (13):4464-71 [15240538.001]
  • [Cites] Genes Dev. 2000 Feb 15;14 (4):391-6 [10691731.001]
  • [Cites] Cell Growth Differ. 2001 Jul;12 (7):363-9 [11457733.001]
  • [Cites] Mol Cell Biol. 1992 Dec;12(12):5447-54 [1448077.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3915-8 [10463582.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):869-74 [11550160.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):353-62 [11745414.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1831-7 [12060624.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Oct;125(10):577-81 [10473871.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Virchows Arch. 1999 Dec;435(6):596-605 [10628802.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] BMC Cancer. 2005 Jul 21;5:84 [16035955.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3516-22 [10589766.001]
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):32631-7 [10551817.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3A):1527-33 [10928066.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):794-9 [8306343.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):701-8 [8690636.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2911-6 [11306467.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):48-53 [9524708.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1129-35 [15709180.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1192-202 [12128120.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2000;35(2):71-103 [10821478.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1055-63 [12209691.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • (PMID = 17103226.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


94. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, Kuwano M, Tsuneyoshi M: ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer; 2005 May 10;114(6):854-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The phenomenon of multidrug resistance (MDR) in various malignant neoplasms has been reported as being caused by one or multiple expressions of ATP-binding cassette (ABC) superfamily protein, including P-glycoprotein/multidrug resistance (MDR) 1 and the MDR protein (MRP) family.
  • In 86 cases of surgically resected soft tissue sarcoma, intrinsic mRNA levels of MDR1, MRP1, MRP2 and MRP3 were assessed using a quantitative reverse transcriptase-PCR (RT-PCR) method.
  • Among the various histologic types, malignant peripheral nerve sheath tumor (MPNST) showed significantly high levels of MDR1 (p=0.017) and MRP3 (p=0.0384) mRNA expression, compared to the other tumor types.
  • P-gp expression was significantly correlated with large tumor size (> or =5 cm, p=0.041) and high AJCC stage (stages III and IV) (p=0.0365).
  • Our results suggest that MDR1/P-gp expression may have an important role to play in tumor progression in the cases of soft tissue sarcoma, and p53 may be one of the active regulators of the MDR1 transcript.
  • In addition, the high levels of both MDR1 and MRP3 mRNA expression in MPNST may help to explain the poor response of this tumor to anticancer-drugs.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette Transporters / genetics. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Genes, p53. Sarcoma / drug therapy. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609299.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters
  •  go-up   go-down


95. Naikmasur VG, Guttal KS, Kaveriappa S, Datta KS: Rapidly progressing soft tissue mass of the anterior mandibular region. Malignant peripheral nerve sheath tumor. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May;107(5):607-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly progressing soft tissue mass of the anterior mandibular region. Malignant peripheral nerve sheath tumor.
  • [MeSH-major] Mandibular Neoplasms / pathology. Nerve Sheath Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Terminology as Topic

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201222.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Miettinen M, Fetsch JF, Sobin LH, Lasota J: Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol; 2006 Jan;30(1):90-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five of 35 patients with follow-up died of metastatic disease; all of these had a tumor >5 cm, mitotic rate >5/50 HPFs, or both; three of these tumors were located in the duodenum.
  • Most patients with long-term follow-up enjoyed a good prognosis; 2 died of other NF1-associated tumors (malignant peripheral nerve sheath tumors, brain tumor).
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330947.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


97. Rekhi B, Jambhekar NA, Puri A, Agrawal M, Chinoy RF: Clinicomorphologic features of a series of 10 cases of malignant triton tumors diagnosed over 10 years at a tertiary cancer hospital in Mumbai, India. Ann Diagn Pathol; 2008 Apr;12(2):90-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicomorphologic features of a series of 10 cases of malignant triton tumors diagnosed over 10 years at a tertiary cancer hospital in Mumbai, India.
  • A rhabdomyoblastic differentiation in a malignant peripheral nerve sheath tumor is unusual and is termed as a malignant triton tumor.
  • Distinct rhabdomyoblastic cells were identified in the areas of malignant peripheral nerve sheath tumor.
  • Immunohistochemistry confirmed the neurogenic differentiation with varying S-100 expression and the rhabdomyoblastic differentiation with desmin and myoglobin positivity in all cases.
  • Malignant triton tumor is an uncommon tumor associated with an aggressive behavior.
  • [MeSH-major] Nerve Sheath Neoplasms / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. S100 Proteins / analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325468.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


98. Dozois EJ, Wall JC, Spinner RJ, Jacofsky DJ, Yaszemski MJ, Sim FH, Moran SL, Cima RR, Larson DR, Haddock MG, Okuno SH, Larson DW: Neurogenic tumors of the pelvis: clinicopathologic features and surgical outcomes using a multidisciplinary team. Ann Surg Oncol; 2009 Apr;16(4):1010-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenic tumors of the pelvis: clinicopathologic features and surgical outcomes using a multidisciplinary team.
  • BACKGROUND: Few data exist regarding the outcomes in patients undergoing surgery for pelvic tumors of neurogenic origin.
  • Our aim was to characterize the clinical and pathologic features of pelvic neurogenic tumors and assess surgical outcomes.
  • METHODS: All patients who underwent operations for pelvic neurogenic tumors at our institution between 1956 and 2004 were identified.
  • Malignant lesions were found in 43 patients (48%).
  • Schwannomas were the most common benign tumor (61%) and malignant peripheral nerve sheath tumors the most common malignant lesion (81%).
  • Median tumor size was 9.5 cm (range 0.8-32 cm).
  • Malignant tumors had histopathologic evidence of infiltration of surrounding structures in 49% of cases.
  • Intralesional resection was the most common surgical technique for both benign and malignant tumors.
  • Adjuvant therapy was given to 91% of the patients with malignant disease.
  • Five-year local recurrence rates for benign and malignant lesions were 35.9% and 35.0%, respectively.
  • Distant recurrence for malignant lesions was 65.1% at 5 years.
  • Five-year disease-free survival for malignant tumors was 25.9%.
  • CONCLUSION: Pelvic neurogenic tumors occurring in young patients may be large when detected and present with nonspecific symptoms.
  • Benign and malignant tumors had a high local recurrence rate and survival for malignant tumors was poor.
  • [MeSH-major] Neoplasms, Nerve Tissue / pathology. Neoplasms, Nerve Tissue / surgery. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Patient Care Team. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194756.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC: Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer; 2010 Jan 15;116(2):451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.
  • BACKGROUND: Correct pretreatment classification is critical for optimizing diagnosis and treatment of patients with peripheral nerve sheath tumors (PNSTs).
  • The aim of this study was to evaluate whether F18-fluorodeoxyglucose positron emission tomography (FDG PET) can differentiate malignant (MPNST) from benign PNSTs.
  • METHODS: Thirty-four adult patients presenting with PNST who underwent a presurgical FDG PET/computed tomography (CT) scan between February 2005 and November 2008 were included in the study.
  • Tumors were characterized histologically, by FDG maximum standardized uptake value (SUV(max) [g/mL]), and by CT size (tumor maximal diameter [cm]).
  • The accuracy of FDG PET for differentiating MPNSTs from benign PNSTs (neurofibroma and schwannoma) was evaluated by receiver operating characteristic (ROC) curve analysis.
  • SUV(max) was significantly higher in MPNST compared with benign PNST (12.0 +/- 7.1 vs 3.4 +/- 1.8; P < .001).
  • By ROC curve analysis, SUV(max) reliably differentiated between benign and malignant PNSTs (area under the ROC curve of 0.97).
  • Given the difficulties in clinically evaluating PNST and in distinguishing benign PNST from MPNST, FDG PET imaging should be used for diagnostic intervention planning and for optimizing treatment strategies.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med. 2001 Oct;28(10):1541-51 [11685498.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2856-63 [19351756.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):542-6 [11914894.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):29-43 [12533638.001]
  • [Cites] Eur J Surg Oncol. 2003 Aug;29(6):536-41 [12875862.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:25S-35S [14736833.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):971-4 [15039173.001]
  • [Cites] J Nucl Med. 2004 May;45(5):797-801 [15136629.001]
  • [Cites] Lab Invest. 1983 Sep;49(3):299-308 [6310227.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Ann Surg Oncol. 1995 Mar;2(2):126-31 [7728565.001]
  • [Cites] Med Phys. 1998 Oct;25(10):2046-53 [9800714.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2270-5 [15484214.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):603-7 [15809482.001]
  • [Cites] Orthop Clin North Am. 2006 Jan;37(1):15-22 [16311108.001]
  • [Cites] Nat Med. 2006 Jan;12(1):122-7 [16341243.001]
  • [Cites] Virchows Arch. 2006 Dec;449(6):673-81 [17103226.001]
  • [Cites] AJR Am J Roentgenol. 2007 Oct;189(4):928-35 [17885067.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):390-4 [17932395.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):353-7 [10675220.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1509-17 [11083540.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1336-40 [11585292.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):715-20 [18245531.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):340-9 [18286466.001]
  • [Cites] J Nucl Med. 2008 Jul;49(7):1038-46 [18552153.001]
  • [Cites] Oral Dis. 2008 Sep;14(6):510-3 [18826382.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 May;36(5):751-7 [19142634.001]
  • [ErratumIn] Cancer. 2010 Feb 1;116(3):775
  • (PMID = 19924789.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA086306; United States / NCI NIH HHS / CA / 5 P50 CA086306
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS324300; NLM/ PMC3188986
  •  go-up   go-down


100. Kretschmer T, Antoniadis G, Heinen C, Börm W, Scheller C, Richter HP, Koenig RW: Nerve sheath tumor surgery: case-guided discussion of ambiguous findings, appropriateness of removal, repeated surgery, and nerve repairs. Neurosurg Focus; 2007;22(6):E19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nerve sheath tumor surgery: case-guided discussion of ambiguous findings, appropriateness of removal, repeated surgery, and nerve repairs.
  • In this article the authors attempt to raise awareness of the pitfalls and controversial issues in nerve tumor surgery.
  • In a case-guided format, examples of ambiguous findings, inappropriate tumor removal, repeated surgery, and nerve repairs are provided.
  • The authors also discuss the need to establish a correct diagnosis preoperatively and to avoid the erroneous identification of malignant peripheral nerve sheath tumors (MPNSTs).
  • They emphasize that not all of the principles of soft tissue sarcoma treatment protocols are applicable to MPNST.
  • A situation of repeated surgery for supposedly malignant tumor is described, and an outline of the indications for, and an approach to, repair after lesion removal is given.
  • [MeSH-major] Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / surgery. Neurosurgical Procedures / methods. Peripheral Nerve Injuries. Peripheral Nerves / surgery. Reconstructive Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Reoperation / adverse effects. Reoperation / methods

  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613210.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down






Advertisement